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 ABSTRACT 
 
Engineering Lipid-stabilized Microbubbles for Magnetic Resonance Imaging 
guided Focused Ultrasound Surgery 
 
         Jameel Adebayo Feshitan 
 
 
Lipid-stabilized microbubbles are gas-filled microspheres encapsulated with a 
phospholipid monolayer shell. Because of the high echogenicity provided by its highly 
compressible gas core, these microbubbles have been adapted as ultrasound contrast agents for a 
variety of applications such as contrast-enhanced ultrasonography (CEUS), targeted drug 
delivery and metabolic gas transport.  Recently, these lipid-stabilized microbubbles have 
demonstrated increased potential as theranostic (therapy + diagnostics) agents for non-invasive 
surgery with focused ultrasound (FUS).  For instance, their implementation has reduced the 
acoustic intensity threshold needed to open the blood-brain-barrier (BBB) with FUS, which 
potentially allows for the localized delivery of drugs to treat neurodegenerative diseases such as 
Alzheimer’s, Parkinson’s and Huntington’s diseases. However, the effectiveness of 
microbubbles for this application is dependent on successful microbubble engineering. One 
necessary improvement is the development and utilization of monodisperse microbubbles of 
varying size classes. Another design improvement is the development of a microbubble construct 
whose fragmentation state during or after FUS surgery can be tracked by magnetic resonance 
imaging (MRI).   
Thus, in this thesis, we describe a method to generate and select lipid-coated gas-filled 
microbubbles of specific size fractions based on their migration in a centrifugal field.  We also 
detail the design and characterization of size-selected lipid-coated microbubbles with shells 
 containing the magnetic resonance (MR) contrast media Gadolinium (Gd(III)), for utility in both 
MR and ultrasound imaging. Initial characterization of the lipid headgroup labeled Gd(III)-
microbubbles by MRI revealed that the Gd(III) relaxivity increased after microbubble 
fragmentation into non-gas-containing lipid vesicles. This behavior was explained to stem from 
an increase in interaction between water protons and the Gd(III)-bound lipid fragments due to an 
increase in lipid headgroup area after microbubble fragmentation. To explore this hypothesis, an 
alternative construct consisting of Gd(III) preferentially bound to the protective poly(ethylene 
glycol) (PEG) brush of the lipid shell architecture was also designed and compared to the lipid 
headgroup-labeled Gd(III) microbubbles.  Nuclear magnetic resonance (NMR) analysis revealed 
that, in contrast to the headgroup labeled Gd(III) microbubbles, the relaxivity of the PEG-labeled 
Gd(III)-microbubbles decreased after microbubble fragmentation. NMR analysis also revealed 
an independent concentration-dependent enhancement of the transverse MR signal by virtue of 
the microbubble gas core.  The results of this study illustrated the roles that Gd(III) placement on 
the lipid shell and the presence of the gas core may play on the MR signal when monitoring 
Gd(III)-microbubble cavitation during non-invasive surgery with FUS.  
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Chapter 1: Introduction  
Gas-filled microbubbles are 1 to 100 µm spheres that create a colloidal suspension consisting 
of gas globules dispersed in a liquid medium. These microbubbles occur naturally in fresh or 
seawater, in the fluid within our bodies, or are synthetically manufactured.  Although adaptable 
in a wide range of applications, their use in the medical field is currently gaining ground. For 
example, microbubbles have been studied as tools for contrast-enhanced ultrasonography 
(CEUS), targeted drug/gene delivery and metabolic gas delivery.  Another developing medical 
application with microbubbles involves their application as theranostic (therapy + diagnostic) 
agents for non-invasive surgery using focused ultrasound (FUS).  Ultrasound in combination 
with microbubble cavitation can focus the mechanical energy to microscale events distributed 
throughout the insonified vasculature, resulting in violent or subtle changes to the local 
environment.  A combination of this effect with the capability of microbubbles to simultaneously 
offer contrast enhancement for diagnostic imaging and drug loading, as well as delivering a 
payload for targeted therapy, makes for a promising medical tool (Sirsi and Borden 2009).  
However, there is still a need to improve the design of microbubbles for their successful 
application in FUS surgery. These improvements may include the choice of surfactant shell type, 
reducing microbubble size polydispersity, gas choice and the ability to monitor therapy with 
techniques like MRI. Although a variety of microbubble shell materials may be selected, lipid-
shelled microbubbles are preferred due to their ultrasound compliance (Bloch, Wan et al. 2004; 
Ferrara, Pollard et al. 2007).  Thus, in this chapter, we discuss the structure and composition of 
lipid-stabilized microbubbles, their fabrication methods, the importance of size monodispersity 
and the need for a MRI-detectable microbubble design to aid in tracking of the microbubble or 




1.1. Lipid-shelled Microbubble Structure and Composition 
Lipid-shelled microbubbles are typically composed of two key components: the amphiphilic 
phospholipid moiety and a poly(ethylene glycol) (PEG) labeled lipid emulsifier or lipopolymer 
(Figure 1.1). The inclusion of the PEGylated lipid into the shell improves microbubble stability.   
 
 
Figure 1.1. Cartoon illustrating the microbubble lipid-shelled monolayer 
 In a comparable engineering design to long-circulation liposomes, the brush layer of PEG chains 
is an important part of the lipid microbubble shell structure because it forms a steric barrier 
against coalescence and adsorption of macromolecules to the microbubble surface (Klibanov, 
Maruyama et al. 1990; Klibanov 1999).  The protective role of PEG is assumed to be due to the 
steric hindrance effect of the polymer brush, which forms a semi-impenetrable barrier over part 
of the microbubble surface that partly inhibits certain molecules from diffusing into the brush 
layer (Needham, Mclntosh et al. 1998).   
The main phospholipid component of the shell consists of long hydrophobic fatty acid 
tails and a hydrophilic polar headgroup.  During microbubble formation, these phospholipids 
spontaneously absorb from lipid vesicles in solution such as micelle and liposomes, to form a 
highly oriented and densely packed monolayer at the gas–liquid interface, such that their 




Phospholipids below their main phase transition temperature (Tm), defined as the temperature at 
which the membrane transforms from a crystalline state to a liquid crystalline, can achieve lateral 
compression within the monolayer plane that results in very low surface tension (Ferrara, Pollard 
et al. 2007).  The length of the lipid chain is integral to microbubble stability and affects its 
mechanical properties.  For instance, increasing the length of the lipid chain has been found to 
reduce surface tension and increase shell surface viscosity, buckling stability and  gas permeation 
resistance (Borden and Longo 2002; Kim, Costello et al. 2003; Borden and Longo 2004; Duncan 
and Needham 2004; Pu, Borden et al. 2006; Kwan and Borden 2010).   
Research has also revealed the complex interaction of the lipid shell constituents 
stabilizing the microbubble.  Kim et al. (Kim, Costello et al. 2003) revealed the lipid shell to 
consist of planar microdomain phases separated by regions of defects.  Borden et al. (Borden, 
Martinez et al. 2006) later elucidated the nature of the phase separation on the shell. The 
microdomains were composed mainly of lecithin and were segregated by grain boundary regions 
consisting of a miscible phase rich in other monolayer constituents such as lipopolymers.  Both 
phases are integral in the stability of lipid-stabilized microbubbles (Pu, Borden et al. 2006; Talu, 
Lozano et al. 2006; Ferrara, Pollard et al. 2007). 
  
1.2. Fabrication Techniques 
 The most common technique for generating high yields of lipid-coated microbubbles is by 
mechanical agitation (Feinstein, Shah et al. 1984; Feinstein 2004). This process can be sub-
divided into two techniques, shaking or acoustic emulsification (sonication) at the interface of a 
gas and liquid. Both techniques can produce microbubble suspensions rapidly (~10-40 seconds) 




distribution, ranging between 1-100 microns in diameter. For biomedical applications requiring 
small quantities of microbubbles, the shaking method (Unger et al. 1992), allows for on-site 
generation of microbubbles by vigorously shaking a serum vial (2 – 3 mL) containing lipid 
solution and gas headspace.  This technique has been adapted in the development of 
commercially available lipid microbubbles such as DefinityTM (Lantheus Medical Imaging, 
North Billerica, MA, USA).  The advantage of this technique is that the pre-microbubble lipid 
solution can be stored, and the microbubble suspension can be later prepared using equipment 
such as a dental amalgamator.  Alternatively, the sonication technique is generally used for 
laboratory applications requiring large volumes of polydisperse microbubbles (figure 1.2).  In 
this methodology, microbubbles are generated by mechanical perturbation produced by an 
ultrasonic probe sonifier (at about 10 kHz), whose tip is placed close to the interface of the lipid 
suspension and the overhead gas space.  The technique has been improved in recent years.  For 
instance, Swanson et al. (Swanson, Mohan et al. 2010) adapted the sonication technique to semi-
continuously create lipid-coated oxygen microbubble suspensions at concentrations up to 1010 







Figure 1.2. Representative size distribution of freshly made microbubbles (prepared by 
sonication) measured by light obscuration. 
Other more refined techniques have been developed to produce microbubbles. These 
include the adaptation of T-junctions (Xu, Nie et al. 2005),  flow focusing (Talu, Lozano et al. 
2006; Talu, Hettiarachchi et al. 2008), ink-jet printing (Bohmer, Schroeders et al. 2006) and 
coaxial electrohydrodynamic atomization (Stride and Edirisinghe 2008). These techniques 
mainly make use of microfluidic processing methods to produce microbubbles with narrow size 
distributions. However, these methodologies lack the microbubble production capacity when 
compared to the sonication method.   
 
1.3. Microbubble Size-dependent behavior 
Microbubble size plays a big role on its behavior under ultrasound.  For example, Apfel and 
Holland (Apfel and Holland 1991) developed a Blake threshold, for the onset of inertial 
cavitation of a bubble during pulsed insonation at higher frequencies, by solving mathematical 
models of bubble dynamics. Their calculation demonstrated that the Blake mechanism causes 
unstable growth of smaller bubbles, while liquid inertia restricts the growth of larger bubbles. 




cause bubble fragmentation with bubble size by driving optically observed microbubbles of 
different sizes under a range of ultrasound pressures.  In their analysis, a fragmentation threshold 
was developed to delineate microbubbles that remained intact during ultrasound-induced 
cavitation from those that were destroyed.   
There is also a size-dependent behavior of microbubbles for diagnostic imaging 
applications. In 1933, Minnaert (Minnaert 1933) developed a relationship between acoustic 




















        (1.2) 
where γ represents the polytropic coefficient, ρ represents the density of water, and PA represents 
ambient pressure. One example of an implication of this relation is that increasing the 
microbubble diameter from 1 to 5 microns will change the resonance frequency of an un-
encapsulated microbubble from 4.7 to 0.72 MHz. (Wu and Nyborg 2008).  In a related study, 
Goertz et al. (Goertz, de Jong et al. 2007) showed that, as predicted by a Rayleigh-Plesset model, 
the acoustic response of small (< 2 microns) lipid-coated microbubble led to greater acoustic 
attenuation (extinction) at higher frequencies because they were closer to resonance.
  
.  Microbubble size also affects the biodistribution and pharmacodynamics after 
intravenous injection, the bioeffects during ultrasound insonification, the gas release profile, and 
other related behaviors.  For instance, Bouakaz et al. (Bouakaz, de Jong et al. 1998) 
demonstrated that microbubbles larger than the lung mean capillary (~5 microns) diameter were 
filtered out.  Other studies using positron emission tomography have shown that a large portion 




(Tartis, Kruse et al. 2008).  Clearly, for both diagnostic imaging and therapeutic applications 
microbubbles size control is necessary for their successful development as theranostic agents. 
 
1.4. Attempts to Reduce Size Polydispersity 
        Most commercially available microbubble contrast agents are highly polydisperse in size. 
For example, the commercially available lipid-based microbubble, Definity,  contains 
microbubbles ranging from 1 to 10 microns in diameter, with most of the microbubbles below 2 
microns (Goertz, de Jong et al. 2007).   The high polydispersity is a consequence of the 
emulsification methods (as described in section 1.2) used to generate microbubbles in high 
quantity, such as sonication and shaking. In most cases, the size distribution is broad over a 
range of sub-micrometer to tens of micrometer in diameter. Consequently, a number of methods 
are being developed to improve the control over microbubble size and other characteristics. 
These techniques include flow focusing (Talu, Lozano et al. 2006; Talu, Hettiarachchi et al. 
2007; Talu, Hettiarachchi et al. 2008), T-junctions (Xu, Nie et al. 2005) and 
electrohydrodynamic atomization (Farook, Stride et al. 2007; Farook, Zhang et al. 2007). While 
these techniques provide very low polydispersity, they are rather slow at generating 
microbubbles. Using flow focusing, for example, requires several hours to produce microbubbles 
at sufficient numbers for even a single small-animal trial (∼ 0.1 mL × 109 mL−1). Additionally, 
dust particles can plug microchannels, thus requiring fabrication and calibration of a new device.  
Although engineering breakthroughs may eventually allow efficient and robust generation of 
monodisperse microbubbles via microfluidic strategies, these techniques currently remain 




        Another strategy takes advantage of microbubble buoyancy to isolate monodisperse 
microbubble populations.  In principle, larger microbubbles are more buoyant and rise faster, 
thus allowing separation possible based on different migration rates in a gravitational field. 
Kvale et al. (Kvale, Jakobsen et al. 1996) described a model for the size fractionation of air-filled 
microbubbles by simple flotation. Microbubbles were injected at the bottom of a stagnant water 
column and allowed to rise under normal gravity. The model predicted the size distribution of 
microbubbles at certain distances from the bottom of the column as a function of time. The form 
of the model was a second-order PDE (equation 1.3) that used Stokes velocity (equation 1.4) to 
account for the convective motion of the bulk dispersed phase (liquid moved down the column as 
microbubbles moved up) as well as the Stokes-Einstein diffusion constant (equation 1.5) to 







































=      (1.5) 
where uir represents the relative velocity between the microbubble and the fluid, n represents the 
number of microbubbles, t represents time, x represents vertical position, Ri represents 
microbubble radius, g represents gravity, DiB represents diffusion constant, µ* represents 
effective viscosity, ρ – ρ
 i1 represents the density difference between the bubble and the fluid, R 





  Wheatley et al. (Wheatley, Forsberg et al. 2006), described a methodology to separate 
submicron population of bubbles from larger ones by using predetermined centrifugal speeds. 
This centrifugation technique reduced the separation time as compared to the gravity separation 
protocol. By adapting these protocols, it is conceivable to develop a technique to select different 
microbubble size classes by varying centrifugal speed.   
    
1.5. Applications of Microbubbles in Focused Ultrasound Surgery 
1.5.1. Focused Ultrasound Surgery with Microbubbles 
Focused ultrasound (FUS) surgery has become a promising medical technique since it 
provides a truly non-invasive surgical method without the unwanted side effects associated with 
other treatment option like chemotherapy and radiotherapy (Kennedy, ter Haar et al. 2003). 
When ultrasonic waves are focused using transducers with spherical geometries, or beam 
steering techniques, the ultrasonic waves align to form a focal region a certain distance from the 
plane of the transducer leading to localization of the acoustic energy to a target region without 
significantly perturbing the surrounding media.  The ability of high intensity FUS to induce 
lesion formation for non-invasive surgery is based on the observation that above a certain 
thermal threshold and sonication time, irreversible cell death occurs through “coagulative 
necrosis” (Kennedy, ter Haar et al. 2003).   Ultrasound can be used to generate non-thermal 
bioeffects like the acoustic cavitation generated by bubbles (Kennedy, ter Haar et al. 2003; Jolesz 
and McDannold 2008).  At high acoustic intensities, these gas bubbles can form in the focal area 
during the rarefaction phase of ultrasound. These inception bubbles oscillate in size or undergo 




the microenvironment (Kennedy, ter Haar et al. 2003; Hindley, Gedroyc et al. 2004), which 
further aids the therapy.    
While heating with inception microbubble cavitation may provide some advantages over 
heating alone, it has its disadvantages. For instance, the forces generated from inertial cavitation 
from an inception bubble can cause significant tissue damage.  Moreover, the uncertainty in 
formation and location of inception cavitation may result in tissue damage outside the desired 
region of interest. One method to mitigate the potential problems with cavitation-enhanced FUS 
is to introduce preformed lipid-stabilized microbubbles into the vasculature (Jolesz and 
McDannold 2008).  Since these microbubbles, are already commercially available as ultrasound 
contrast agents, they can substantially reduce the threshold for inertial cavitation and further 
reduce the acoustic power requirements needed to ablate tissue.  These preformed microbubbles 
have been demonstrated in animals to aid lesion formation through non-thermal mechanisms.  
For example, Fujishiro et al. (Fujishiro, Mitsumori et al. 1998) demonstrated an increase 
ultrasound-induced heating efficiency of a 2 centimeter beef tissue phantom with the 
administration of air-filled protein shelled microbubbles. In a related study, Miller et al. (Miller 
and Gies 1998) demonstrated the importance of microbubble persistence in their efficacy for 
ultrasound-induced cavitation. Generally, perflourocarbon-containing microbubbles were 
reported to be more effective in inducing hemolysis in the canine blood than air-containing 
microbubbles. Mcdonnald et al. (McDannold, Vykhodtseva et al. 2006) showed that, upon 
administration of protein-shelled microbubbles (Optison, GE Healthcare, Milwaukee, WI), lesion 
formation in the rabbit brain could be attained a temperature below the threshold for thermal 
damage.  Finally, in a study comparing different microbubbles shell architectures, Takegami et 




ImaRX, Tuscon, Arizona) were more efficient in inducing lesions in the rabbit liver than protein-
shelled counterparts. Clearly, varying parameters in microbubble design such as the choice of 
shell, gas-type and size are important considerations in the development of microbubbles for 
non-invasive surgery with FUS.  
 
1.5.2. Magnetic Resonance Imaging (MRI)-guided Focused Ultrasound Surgery with 
Microbubbles 
Another important consideration in the clinical application of FUS surgery is the ability to 
monitor treatment accurately.  In modern practice this is achieved by either using real-time 
ultrasound (Madersbacher, Kratzik et al. 1994; Wu, Chen et al. 2001), or MRI (Cline, Schenck et 
al. 1992; Hynynen, Darkazanli et al. 1993; Cline, Hynynen et al. 1995; Hynynen, Freund et al. 
1996).  The advantage in using MRI to guide FUS therapy is the capability of producing better 
image quality and the ability to monitor changes in temperature.  This treatment is called MRI-
guided focused ultrasound surgery (MRIgFUS).  In this method, the target region is initially 
identified with “sublesioning” ultrasound exposures (Jolesz and McDannold 2008).  
Subsequently, the local rise in temperature is used to validate the position of the ultrasound focus 
before higher intensity pulses are used for the actual treatment.  The Exablate 2000 is an example 
MRIgFUS device, developed by Insightec Ltd, that is currently FDA approved to treat uterine 
fibroids, a benign tumor found in the uterus.  This device allows the operator to monitor and treat 
the tumor in real time via a thermal feedback control loop.  McDannold et al. (McDannold, 
Vykhodtseva et al. 2006) demonstrated that the initiation and level of lesion formation in rabbits, 
created using the combination of FUS and an ultrasound contrast agent (Optison), correlated with 




administration of the microbubbles reduced the acoustic threshold needed to produce the lesions 
by 91 % as compared to without microbubbles.  While MRIgFUS is currently under 
development to treat a variety of other diseases found in the liver, uterus, kidney and bone, one 
of the most ideal applications is to treat diseases found in the brain (Jolesz and McDannold 
2008). 
 
1.5.3. Blood-Brain-Barrier Opening with Focused Ultrasound and Microbubbles 
A method that allows non-invasive and efficient delivery of drugs to anatomically desired 
regions of the brain currently does not exist. The key challenge in this development is severe 
limitation imposed by action of the blood-brain-barrier (BBB).  In general, the BBB is a 
permeability barrier that prevents most large compounds (> 400 Da) from crossing into the 
interstitial space of the brain (Pardridge 2005).  Thus, it serves as a major bottleneck for drug 
delivery to the brain to treat neurodegenerative diseases such as Parkinson’s, Huntington’s and 
Alzheimer’s, as most effective drugs are larger than the BBB size cut-off. While other invasive 
or non-localized strategies are under development to overcome the BBB, FUS with pre-
administered microbubbles represents one of the only non-invasive and localized methodologies 
available (Choi, Pernot et al. 2007). The intravenous addition of microbubble before sonication 
has improved safety of FUS-induced BBB opening since it is not associated with significant 
neuronal damage. BBB opening with FUS and microbubbles relies mainly on non-thermal 
mechanical perturbation mechanisms caused by the interaction of the microbubbles with 
ultrasound as opposed to the predominantly thermal effects used to induce tissue ablation in 
MRIgFUS.  Furthermore, the BBB disruption is reversible since it recovers within a few hours.  




the acoustic driving pressure needed for non-thermal cell disruption.  Hynyen et al. (Hynynen, 
McDannold et al. 2001) demonstrated that FUS sonication in the presence of pre-injected 
Optison microbubbles temporarily opens the BBB in rabbits at acoustic intensity levels lower 
than that required for thermal ablation. Choi et al. (Choi, Pernot et al. 2007) further demonstrated 
the non-invasive, localized and transient opening of the BBB in mice at lower acoustic driving 
pressures, with the administration of the lipid-stabilized microbubble Definity.  
  
1.5.4. The Need for MRI-detectable Microbubbles in MRI-guided Focused Ultrasound 
Surgery and Blood-Brain Barrier Opening with Focused Ultrasound 
Until now, the microbubble sizes used for FUS-induced BBB opening were generally 
polydisperse in nature (Figure 1.2), similar to those formed by sonication or shaking, thus 
resulting in the unknown dependence of bubble size on FUS-induced BBB opening.  
Additionally, owing to the different cavitation modes of microbubbles during FUS sonications, 
the state of the microbubble construct during or after therapy is not known. Providing solutions 
to these problems begins with proper microbubble engineering. For instance, the dependence of 
microbubble size on BBB opening may be elucidated by developing and testing the effects of 
different-sized monodisperse microbubbles. The monodisperse microbubbles size classes could 
be prepared using the centrifugation technique proposed in section 1.4.  Furthermore, the 
question of how to track the microbubble fragmentation state during or after FUS-induced BBB 
opening or MRIgFUS may be answered by taking advantage of the techniques used to determine 
the opening and closing of the BBB.  In most BBB opening studies, this involves monitoring MR 
signal intensity changes after administration of  MRI contrast media, typically Gadolinium 




the injection of the MRI contrast media after microbubble-mediated BBB opening results in 
enhancement in the MRI signal intensity in the sonicated region. This is because these Gd(III) 
molecules are able to diffuse into the extracellular space, previously unreachable when the BBB 
is closed. One may gain insight on the final state of the lipid-stabilized microbubble by 
developing a contrast agent that combines both imaging modalities, ultrasound with 
microbubbles and MRI with Gd(III). Thus, the development of size-selected microbubbles with 
Gd(III) bound lipid shells could be beneficial to advance both MRIgFUS and BBB opening with 
FUS. The development of this dual-modal contrast agent may also give information on shell-
associated biodistribution and pharmacokinetics for drug delivery to the brain, since the Gd(III)-
bound lipid shell can serve as a potential drug surrogate. Finally, by monitoring the effect of 
microbubble destruction on the MRI signal, one may conceivably use Gd(III) microbubble 
fragmentation as a guide for FUS surgery as opposed to MR thermometry used in MRIgFUS. 
 
1.6. Gadolinium as an MRI contrast agent 
Before development of a dual-modal construct for ultrasound and MRI, it is necessary to 
understand the functionality of the contrast media conventionally used in MRI. Historically, MRI 
contrast agents play a significant role in the development of MRI for medical applications.  They 
are commonly referred to as T1- or T2-agents based on whether the relative reduction in 
relaxation times caused by the agent is larger for the longitudinal (T1) or transverse (T2) 
relaxation (Toth, Helm et al. 2002). MR signal intensity increases with increasing 1/T1 (brighter 
T1-weighted images) and reduces with increasing 1/T2 (darker T2-weighted images). While a 
variety of other contrast agents exist, such as iron-oxide based particles, the most popularly used, 




Gd(III) is the ideal contrast agent because of its slow electron spin relaxation and because its 
seven unpaired electrons makes it the most paramagnetic of all the stable metal ions (Caravan, 
Ellison et al. 1999; Kubicek and Toth 2009).  
 
1.6.1. Relaxivity of Gd(III) based contrast agents 
Solomon, Bloembergen and others  (Bloembergen, Purcell et al. 1948; Solomon and 
Bloembergen 1956; Bloembergen 1957; Bloembergen and Morgan 1961; Connick and Fiat 
1966) provided detailed description of the relaxation of solvent nuclei around a paramagnetic 
center. As equation 1.6 below shows, the observed solvent relaxation rate, 1/Ti, obs , is the 
summation of the diamagnetic term 1/Ti, d , corresponding to the relaxation rate of the solvent 
nuclei without the paramagnetic solute, and a paramagnetic term 1/Ti, p which is the relaxation 










      i = 1,2    (1.6) 
 
This paramagnetic contribution is linearly proportional to the concentration of paramagnetic, 
[Gd(III)] :      
 






+=    i = 1, 2  (1.7) 
 
where the parameter ri is the longitudinal or transverse proton relaxivity (mM–1s–1), defined as 




described by Toth et al. (Toth, Helm et al. 2002), the two key contributors to overall 
paramagnetic relaxation rate enhancement and/or relaxivity are the inner sphere, due to the 
interaction between the Gd(III) electron spins and the water protons in the first coordination 
sphere, and the outer sphere contribution, arising from random translational diffusion of bulk 










































     (1.9) 
 
where riIS = 1/Ti,pIS and riOS = 1/Ti,pOS and IS and OS stand for inner and outer sphere 
respectively.  Efforts to improve the relaxivity of contrast agents generally involve increasing the 
inner sphere term since the outer sphere contribution can hardly be modified (Toth, Helm et al. 
2002).  The most important factors governing relaxivity that can be modified are the rotational 
correlation time, proton exchange and the hydration number, q (Toth, Helm et al. 2002; Kubicek 
and Toth 2009).  However, most efforts to improve relaxivity involve increasing the rotational 
correlation time by binding Gd(III) to macromolecular compounds like proteins, polymers and 
lipids structures (Toth, Helm et al. 2002; Strijkers, Mulder et al. 2005; Hermann, Kotek et al. 







1.7. Microbubbles as MRI Contrast Agents 
1.7.1. Microbubbles as Contrast Agents for T2*-weighted MRI 
  Gas-filled microbubbles have been previously adapted mainly as T2* MR contrast agents. 
Studies have demonstrated that microbubbles (without attached MRI contrast media) can 
enhance T2* shortening (Alexander, McCreery et al. 1996; Wong, Huang et al. 2004; Cheung, 
Chow et al. 2009).  T2* is the additional enhancement of the transverse magnetization signal 
above of baseline provided by T2 and stems from inhomogeneities in the magnetic field.  
Previous results have demonstrated this T2* shortening effect to be microbubble concentration-
dependent.  Alexander et al. (Alexander, McCreery et al. 1996) reported T2* shortening from 9 
different gas-types and the potential to use the gas-volume dependent susceptibility effect as a 
pressure sensor for evaluating cardiovascular function.  Cheung et al. (Cheung, Chow et al. 
2009) reported T2* shortening at 7 T in the rat brain as a function of microbubble volume fraction 
for both sulfur hexafluoride and air-filled microbubbles.  Wong et al. (Wong, Huang et al. 2004) 
used the T2* shortening induced by Optison (GE Healthcare) microbubbles for intravascular 
imaging of the rat liver with MRI.  Subsequent studies by Chow et al. (Chow, Chan et al.) and 
Yang et al. (Yang, Li et al. 2009) demonstrated additional T2* shortening by loading  iron oxide 
into the shell of polymeric microbubbles (Chow, Chan et al. ; Yang, Li et al. 2009).  Finally, Liu 
et al. (Liu, Lammers et al. 2011) reported an additional T2* shortening after polymeric 
microbubble fragmentation with ultrasound.  The additional shortening after microbubble 






1.7.2. Microbubbles as Contrast Agents for T1-weighted MRI 
Currently, the adaptation of gas-filled microbubbles for T1-weighted MRI has been limited. 
Ao et al. (Ao, Wang et al. 2010) loaded Gd(III) onto the shell of 1.5-µm diameter polymeric 
microbubbles and demonstrated T1 shortening as a function Gd(III)-loaded microbubble 
concentration. Additionally, Liu et al. (Liu, Lammers et al. 2011) demonstrated that 
fragmentation of iron oxide loaded polymer-shelled microbubbles with ultrasound, not only 
shortened T2*, but also T1.  In another study, Liao et al (Liao, Liu et al. 2012) developed albumin 
microbubbles containing a shell surface-conjugated with Gd(III)-DTPA to serve as dual mode 
contrast agents for ultrasound and MR imaging.  However, the problem with previously designed 
MRI contrast media loaded microbubbles for FUS surgery is that shell material has mainly been 
polymer or protein based, which is not ideal for FUS surgery due to their stiffness and limited 
ultrasound compliance (Bloch, Wan et al. 2004; Ferrara, Pollard et al. 2007; Sirsi and Borden 
2009).  Adaptation of Gd(III)-loaded lipid-shelled microbubbles may potentially solve this 
problem.    
  
1.8.   Research Motivations and Specific Aims  
Microbubbles are ubiquitous in nature and are important for many industrial and clinical 
applications. Over the past several decades, microbubbles have been developed for biomedical 
applications such as CEUS, targeted drug delivery and metabolic gas delivery. Due to their high 
echogenicity, acoustic response and biocompatibility, lipid-stabilized microbubbles are most 
commonly desired for these applications. More recently, these lipid-stabilized microbubbles have 
been adapted for non-invasive surgery with FUS. For instance, microbubbles have been 




and at a lower acoustic driving pressure than with convention high intensity FUS and inception 
microbubbles (Hynynen, McDannold et al. 2001; Choi, Pernot et al. 2007).  However, the 
microbubbles used in previous studies tended to be highly polydisperse in size, which poses a 
problem since their behavior under ultrasound is very size dependent.  Thus, in order to 
understand the dependence of microbubble size on FUS-induced BBB opening, a technique that 
efficiently selects different microbubbles classes is necessary.  Additionally, since the 
fragmentation state of a microbubble during or after FUS varies depending on microbubble size 
and ultrasound driving parameters, a means to detect the final fragmentation state of a 
microbubble is desired. To address these issues this research project was proposed to accomplish 
to following aims: 
 
Specific Aims: 
1. Develop a method to size select different microbubble size classes rapidly and efficiently 
with centrifugation.  
2. Develop a means to conjugate an MRI contrast agent, Gd(III,) to the shell of the lipid 
microbubble architecture without sacrificing microbubble size monodispersity. 
3. Characterize the MR behavior of the Gd(III)-bound size-selected lipid-shelled 
microbubbles before and after fragmentation with ultrasound. 
 
The following hypotheses were made regarding these specific aims: 
1. Microbubbles are large enough such that Brownian forces are neglected during 




2. Hydrodynamic interaction of multiple microbubbles during centrifugal separation can be 
accounted for by a second order correlation of the effective fluid viscosity.  
3. Lipid-shelled microbubbles are robust enough to withstand the centrifugation speeds (up 
to 300 times gravity) without significant degradation. 
4. Individual Gd(III)-ligand molecules cannot bind to multiple binding sites at the same 
time. 
5. Post-labeling of the Gd(III)-ligand chelate to the lipid groups on the microbubble is more 
efficient and more cost effective than pre-labeling.  
6. The heating from Gd(III) ligand chelation reaction does not significantly degrade 
microbubble architecture provided it is below the phase transition temperature of the 
main lipid headgroup. 
7. Fragmentation/destruction of Gd(III)-bound lipid-shelled microbubbles with a 
combination of ultrasound and heating above the phase transition temperature of the main 





Chapter 2:  Microbubble Size Isolation by Differential Centrifugation 
2.1. Introduction 
 Microbubbles are being employed for several biomedical applications, including contrast 
enhanced ultrasound (Feinstein 2004; Lindner 2004), drug and gene delivery (Ferrara, Pollard et 
al. 2007; Hernot and Klibanov 2008) and metabolic gas delivery (Burkard and Vanliew 1994; 
Kheir, Zurakowski et al. 2007).  Microbubbles react strongly to ultrasonic pressure waves by 
virtue of their compressible gas cores, which resonate at the MHz-frequencies used by current 
clinical scanners.  Oscillation of the gas core allows re-radiation (backscatter) of ultrasound 
energy to the transducer at harmonic frequencies and nonlinear modes, thus providing exquisite 
sensitivity in detection with current contrast-enhanced pulse sequences and signal processing 
algorithms.  Additionally, microbubbles may cavitate stably or inertially to facilitate drug release 
(Borden, Kruse et al. 2005; Lum, Borden et al. 2006) and extravascular delivery (Choi, Pernot et 
al. 2007; Stieger, Caskey et al. 2007) within the transducer focus. 
 Current commercially available microbubble formulations are polydisperse in size.  In 
most cases, the size distribution is broad over a range of submicron to tens of microns in 
diameter.  This is problematic because microbubble behavior depends very strongly on size.  For 
example, increasing the microbubble diameter from 1 to 5 µm will change the resonance 
frequency of an unencapsulated microbubble from 4.7 to 0.72 MHz (Wu and Nyborg 2008).  
Microbubble size also affects the biodistribution and pharmacodynamics after intravenous 
injection, the bioeffects during ultrasound insonification, the gas release profile, and other related 
behaviors.  Clearly, microbubbles of a specific size with low polydispersity are desired for 




Efforts to engineer monodisperse microbubble suspensions have mainly focused on 
microfluidic technologies.  These techniques include flow focusing (Talu, Lozano et al. 2006; 
Talu, Hettiarachchi et al. 2007; Talu, Hettiarachchi et al. 2008), T-junctions (Xu, Li et al. 2006) 
and electrohydrodynamic atomization (Farook, Stride et al. 2007; Farook, Zhang et al. 2007).  
While these techniques provide very low polydispersity, they are rather slow at generating 
microbubbles (Pancholi, Farook et al. 2008).  Using flow focusing, for example, requires several 
hours to produce microbubbles at sufficient numbers for even a single small-animal trial (~0.1 
mL x 109 mL-1).  Additionally, dust particles can plug micro-channels, thus requiring fabrication 
and calibration of a new device.  While engineering breakthroughs may eventually allow 
efficient and robust generation of monodisperse microbubbles via microfluidic strategies, these 
techniques currently remain untenable for biomedical studies. 
Mechanical agitation has been the main method to create encapsulated microbubbles for 
biomedical applications, since their inception by Feinstein et al. (Feinstein, Shah et al. 1984).  
Mechanical agitation is a common emulsification procedure in which a hydrophobic phase (i.e., 
gas) is dispersed within an aqueous surfactant solution by disruption of the interface.  Acoustic 
emulsification (sonication), for example, generates large quantities of microbubbles (100 mL x 
1010 mL-1) rapidly and reproducibly within just a few seconds.  Shaking a serum vial with a 
device similar to a dental amalgamator produces a sufficient dose of microbubbles (2 mL x 1010 
mL-1) for a single patient study, at the bedside in under a minute (Unger, Fritz et al. 1999).  
While mechanical agitation is highly efficient at generating microbubbles, the size distributions 
tend to be highly polydisperse and thus are not optimal for biomedical applications. 
The origins of polydispersity in acoustically generated emulsions were elucidated three 




reported to occur in two stages.  Instability at the water surface results in entrainment of drops 
(or bubbles) into the aqueous medium, and subsequent cavitation in the medium results in 
droplet breakup to a critical size (Figure 2.1).   
 
Figure 2.1. Cartoon showing origins of polydispersity during acoustic emulsification. Initial 
bubble entrainment occurs as a capillary instability. Inset shows relevant length scales. 
Subsequent cavitation in the suspension (shown as filled circle with propagating waves) 
induces breakup of the larger bubbles to a critical diameter, where surface forces and 
inertial forces balance. Figure adapted from Li and Fogler (Li and Fogler 1978; Li and 
Fogler 1978). 
The first stage, entrainment, occurs as the unstable growth and eventual eruption of interfacial 
capillary waves produced by sonication.   The second stage of acoustic emulsification involves 
the continual cavitation-induced breakdown of larger particles as a function of sonication time 




and flow pattern around the droplet.  The stable size results when surface tension forces balance 
the inertial forces on the droplet.  Initial and final droplet size is difficult to predict a priori.  The 
analysis provided by Li and Fogler for liquid droplets points to the origin of polydispersity as a 
consequence of multiple mechanisms acting simultaneously on the multi-body system.  Given 
that emulsion polydispersity is inherent in mechanical agitation processes, it is desirable to find a 
means of separating subpopulations of the particles based on size.  This will allow improved 
microbubble formulations for advanced biomedical applications. 
Previous reports have described the use of flotation to isolate subpopulations from 
polydisperse microbubble suspensions.  In principle, larger microbubbles are more buoyant and 
rise faster, thus allowing separation based on different migration rates in a gravitational field.  
Kvale et al. described a model for the size fractionation of air-filled microbubbles by simple 
flotation (Kvale, Jakobsen et al. 1996).  Microbubbles were injected at the bottom of a stagnant 
water column and allowed to rise under normal gravity.  The model predicted the size 
distribution of microbubbles at certain distances from the bottom of the column as a function of 
time.  The form of the model was a second-order PDE that accounted for the convective motion 
of the bulk dispersed phase (liquid moved down the column as microbubbles moved up) as well 
as the Brownian (thermal) diffusive motion of the particles.  The crowding effect of the 
microspheres was accounted for by using a modified version of Einstein’s derivation for the 
effective viscosity in a dilute suspension (Batchelor and Green 1972). 
Wheatley et al. reported the isolation of submicron bubbles using differential 
centrifugation (Wheatley, Forsberg et al. 2006).  Isolation was accomplished by flotation at 
normal gravity, or centrifugation at a relative centrifugal force (RCF) of 16 or 45 for pre-




The use of centrifugation reduced the flotation time, but led to destabilization of the surfactant-
stabilized microbubbles during subsequent insonification.  Microbubbles centrifuged at 45 RCF 
for 1 minute were not stable, whereas those spun at 16 RCF for the same time were relatively 
stable.  Destabilization was attributed to the extra hydrostatic pressure exerted on the 
microbubbles, which increased towards the bottom of the column and in proportion to 
centrifugation speed.  Flotation at normal gravity was more time consuming, but less detrimental 
to microbubble stability. 
 In contrast to surfactant-coated microbubbles, lipid-coated microbubbles have been 
shown to be stable after centrifugation up to several hundred RCF (Takalkar, Klibanov et al. 
2004; Zhao, Borden et al. 2004).  The lipid shell is highly viscous (Kim, Costello et al. 2003) and 
relatively impermeable to gases (Borden and Longo 2004).  We therefore sought to further 
develop the differential centrifugation method of Wheatley et al. (Wheatley, Forsberg et al. 
2006), but as a rapid and facile means to isolate sub-populations of lipid-coated microbubbles.  
Below, we report on the experimental characterization of the initial polydisperse suspension, the 
development of a method to isolate size fractions of interest for biomedical applications, and 
characterization of the long-term stability of the isolated fractions. 
 
2.2. Methods and Materials 
2.2.1. Materials 
All solutions were prepared using filtered, 18MΩ deionized water (Direct-Q, Millipore, Billerica, 
MA).  All glassware was cleaned with 70 vol% ethyl alcohol solution (Sigma-Aldrich; St. Louis, 




(PFB) at 99 wt% purity obtained from FluoroMed (Round Rock, TX).  1,2-distearoyl-sn-glycero-
3-phosphocholine (DSPC) was purchased from Avanti Polar Lipids (Alabaster, AL) and 
dissolved in chloroform (Sigma-Aldrich) for storage.  Polyoxyethylene-40 stearate (PEG40S) 
was obtained from Sigma-Aldrich and dissolved in deionized water.  The fluorophore probe 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiO) solution (Invitrogen; Eugene, OR) was used to 
label the microbubbles for part of the experiments.  
 
2.2.2. Microbubble Generation 
Microbubbles were coated with DSPC and PEG40S at molar ratio of 9:1.  The indicated amount 
of DSPC was transferred to a separate vial, and the chloroform was evaporated with a steady 
nitrogen stream during vortexing for about ten minutes followed by several hours under house 
vacuum.  0.01 M phosphate buffered saline (PBS) solution (Sigma-Aldrich) was filtered using 
0.2-µm pore size polycarbonate filters (VWR, West Chester, PA).  The dried lipid film was then 
hydrated with filtered PBS and mixed with PEG40S (25 mg/mL in filtered PBS) to a final 
lipid/surfactant concentration of 1.0 mg/mL.  The lipid mixture was first sonicated with a 20-kHz 
probe (model 250A, Branson Ultrasonics; Danbury, CT) at low power (power setting dialed to 
3/10; 3 Watts) in order to heat the pre-microbubble suspension above the main phase transition 
temperature of the phospholipid (~55 oC for DSPC) and further disperse the lipid aggregates into 
small, unilamellar liposomes (Kim and Franses 2005).  PFB gas was introduced by flowing it 
over the surface of the lipid suspension.  Subsequently, higher power sonication (power setting 
dialed to 10/10; 33 Watts) was applied to the suspension for about 10 seconds at the gas-liquid 




experiments, DiO solution (1 mM) was added prior to high-power sonication at an amount of 1 
µL DiO solution per mL of lipid mixture. 
 
2.2.3. Microbubble Washing & Lipid Recycling 
The microbubble suspension was collected into 30-mL syringes (Tyco Healthcare, Mansfield, 
MA), which were used as the flotation columns.  Washing and size fractionation by 
centrifugation was performed with a bucket-rotor centrifuge (model 5804, Eppendorf, Westbury, 
NY), which had a radius of approximately 16 cm from the center to the syringe tip and operated 
between 10 and 4500 RPM.  Centrifugation (10 minutes, 300 RCF) was performed to collect all 
microbubbles from the suspension into a cake resting against the syringe plunger.  The remaining 
suspension (infranatant), which contained residual lipids and vesicles that did not form part of 
the microbubble shells, was recycled to produce the next batch of microbubbles.  All resulting 
cakes were combined and re-suspended in PBS to improve total yield. 
 
2.2.4. Size and Concentration Measurements 
Microbubble size distribution was determined by laser light obscuration and scattering 
(Accusizer 780A, NICOMP Particle Sizing Systems, Santa Barbara, CA).  2-µL samples of each 
microbubble suspension were diluted into a 30-mL flask under mild mixing during measurement.  
Size distribution was also determined using the electrozone sensing method (Coulter Multisizer 
III, Beckman Coulter, Opa Locka, Fl).  A 4-µL sample of microbubble suspension was diluted 




(size range of 0.6-18 µm) was used for the measurements.  All samples were measured at least 
three times by either instrument and analyzed for both number- and volume-weighted size 
distributions.   
 
2.2.5. Optical Microscopy 
Direct visual confirmation of microbubble size was performed 48 hours after the samples were 
prepared using an Olympus 1X71 inverted microscope (Olympus; Center Valley, PA).  The 
microbubble samples were taken directly from the serum vials and imaged at room temperature.  
Images were captured in both bright-field and epi-fluorescence modes using a high-resolution 
digital camera (Orca HR, Hamamatsu, Japan) and processed with Simple PCI software (C-
Imaging, Cranberry Township, PA).  A 40X objective was used to capture the images of size-
isolated microbubbles of 4-5 µm diameter, while a 100X oil-immersion objective was used for 
polydispersed microbubbles and size-isolated microbubbles of 1-2 µm diameter. Subsequent 
image analysis was done using ImageJ 1.4g (http://rsb.nih.gov/ij/). 
 
2.2.6. Flow Cytometry 
A FACScan Cell Analyzer (Becton-Dickinson, Franklin Lakes, NJ) was used to characterize 
microbubble fluorescence intensity (FL) and light scattering profiles (FSC and SSC).  Voltage 
and gain settings for FSC, SSC and FL were adjusted to delineate the microbubble populations 




to each measurement.  Subsequent data analysis was done using CellQuest Pro (Becton-
Dickinson, Franklin Lakes, NJ). 
 
2.3. Size Isolation 
Differential centrifugation was used to isolate size-selected microbubbles based on their 
migration in a centrifugal field (Fig. 2.2).  The initial microbubble size distribution and 
concentration was measured and imported into a spreadsheet (Excel, Microsoft, Bellevue, WA) 
in order to determine the number density for each size channel and the total gas volume fraction.  
The spreadsheet was used to calculate the relative centrifugal force (RCF) needed for a 
microbubble size class to rise through the column of length L for a fixed centrifugation time. 
Following Kvale (Kvale, Jakobsen et al. 1996), Stokes’ equation for the rise velocity of a 
buoyant particle relative to the bulk fluid under creeping flow conditions was used as follows: 







= ,       (2.1) 
where subscript i refers to the particle size class, ri is the particle radius and g is the gravitational 
force. The effective viscosity, *2η , of the microbubble suspension was calculated using 

















1 ,        (2.3) 
where Φ is total the microbubble volume fraction for Nd size classes.  Equations 11-13 were used 
to calculate the strength of the centrifugal field (in RCF) for a given initial size distribution, time 
period and syringe column length.  Volume fraction was assumed to be constant over the entire 
column, and acceleration/deceleration effects were neglected. 
 
Figure 2.2. Schematic of differential centrifugation for the size isolation of microbubbles. 
Following production, microbubbles were collected into 30-mL syringes (L = 8.2 cm) and 
washed, as above.  Production-washing was repeated 3-5 times, each time saving the 
microbubble cake and recycling the lipid infranatant.  The cakes were combined and re-dispersed 
into 30 mL of filtered PBS.   We noted that in order to ensure a high yield, the concentration of 
microbubbles after this step should be at least ~1 volume %.  The following protocol was then 
used to isolate microbubbles of 1-2 µm and 4-5 µm diameter.  At least three separate 




least three times each.  A two-tailed parametric unpaired student t-test was used to determine to 
significance between the polydispersity indices (PI) of 1-2 µm and 4-5 µm samples versus that of 
freshly made samples.  
 
2.3.1. Isolation of 4-5 µm Diameter Microbubbles 
Before beginning the isolation process, care was taken to remove large, visible bubbles that may 
have formed during production or subsequent handling.  Microbubbles of greater than 10-µm 
diameter were removed by performing one centrifugation cycle at 30 RCF for 1 min.  The 
infranatant consisting of less than 10-µm diameter microbubbles was saved and re-dispersed in 
30 mL PBS, while the cake was discarded.  Next, microbubbles of greater than 6-µm diameter 
were removed by performing one centrifugation cycle at 70 RCF for 1 min.  The infranatant 
consisting of less than 6-µm diameter microbubbles was saved and re-dispersed to 30 mL PBS; 
the cake was discarded.  Finally, microbubbles of less than 4-µm diameter were removed by 
centrifuging at 160 RCF for 1 min.  This was repeated about 5-10 times, while each time the 
infranatant was discarded and the cake was re-dispersed in filtered PBS.  Alternatively, 12-mL 
syringes (L = 6.3 cm) were employed and centrifuged at 120 RCF for 1 min to improve yield.  
These cycles were repeated until the infranatant was no longer turbid, indicating complete 
removal of microbubbles less than 4 µm.  The final cake was concentrated to a 1-mL volume of 






2.3.2. Isolation of 1-2 µm Diameter Microbubbles 
The infranatant collected from the 4-5 micron isolation was centrifuged at 270 RCF for 1 min for 
one cycle in order to remove microbubbles of approximately 3-µm diameter and above by 
collecting them into the cake.  The infranatant consisted mostly of microbubbles 1-2 µm 
diameter.  The target microbubbles were collected into a concentrated cake by centrifuging at 
300 RCF for 10 min.  The final cake was re-dispersed to a 1-mL volume of 20 vol% glycerol 
solution in PBS and stored in a 2-mL serum vial with PFB headspace. 
 
2.4. Results 
2.4.1. Polydispersity of Freshly Sonicated Microbubbles 
Preparation of microbubbles by sonication of a 50 mL lipid mixture resulted in a polydisperse 
suspension of approximately 109 to 1010 particles mL-1.  Particle sizing with the Accusizer and 
Multisizer showed a distribution ranging from the lower limit of resolution, ~0.5 µm, to greater 
than 15 µm diameter (Fig. 2.3).  A significant portion of the freshly generated suspension 
contained submicron microbubbles, as previously reported (Borden, Martinez et al. 2006).  
Submicron microbubbles also have been observed by static light scattering (Wheatley, Forsberg 
et al. 2006) and freeze-fracture transmission electron microscopy (Brancewicz, Rasmussen et al. 
2006).  For larger microbubbles, the number-weighted distribution tailed off near 6-8 µm 
diameter (Fig. 2.3A).  The volume-weighted distribution, however, showed a significant 
population out to greater than 10 µm diameter (Fig. 2.3B).  Microbubbles with larger diameters 




therefore were chosen in order to judge the samples during size isolation, since this gives a more 
rigorous indication of the central tendency than arithmetic mean in a skewed distribution. 
 
Figure 2.3. Size distributions for freshly sonicated microbubbles. 
Interestingly, the Accusizer consistently measured distinct peaks centered on approximately 1-2, 
4-5, 7-8 and 9-11 µm diameter for each batch of lipid-coated microbubbles.  These peaks were 
evident on the volume-weighted distribution, but they also could be discerned from the number-
weighted distribution.  Similar results were reported previously (Borden, Zhang et al. 2008).  In 
the laboratory, we have observed these peaks for a variety of gas and lipid combinations (data 




measures size based on light obscuration and scattering, the Multisizer utilizes electrical 
impedance sensing of the volume of electrolyte displaced by the microbubble as it passes 
through an orifice.  Interestingly, the multimodal distribution was not observed on the Multisizer, 
which gave a broad distribution with a single peak located at ~1 µm for the number-weighted 
distribution and ~8 µm for the volume-weighted distribution.  From this data, it was unclear 
whether the multimodal distribution was real, and could not be resolved by the Multisizer, or if it 
was an artifact of the Accusizer.  We therefore sought to better characterize the microbubble 
distribution.  
Microscopy allowed direct visual inspection of individual microbubbles from the suspension.  
Bright-field and epi-fluorescence microscopy images are shown in Figure 2.4.  In fluorescence 
mode, microbubbles appeared as bright rings with dark centers, clearly showing uptake of DiO 
into the shell.  In bright-field mode, microbubbles appeared as dark spheres with bright centers.  
Diffraction rings were particularly prevalent for the smaller microbubbles.  This confirmed the 
predominance of gas-filled microbubbles in the suspension.  Analysis of the bright-field images 
using ImageJ indicated that the distribution of the freshly generated microbubbles was 
multimodal, with a mean diameter of 4.0 ± 3.0 µm for the image shown in Figure 2.4A. 
Flow cytometry was used to further characterize the polydisperse microbubbles (Fig. 2.5).  
Forward- (FSC) and side- (SSC) light scattering measurements were taken.  Interestingly, a 
serpentine shape was observed on the dot plot of FSC versus SSC for the polydisperse 
microbubble suspensions, as shown in Figure 2.5A.  The serpentine shape appeared to correlate 
with the distinct peaks found by the Accusizer, lending more support to the validity of a 





Figure 2.4. Microscopy images of initial polydisperse and final size-isolated microbubbles. 
Shown are bright-field images (left) and fluorescence images (right) of the membrane 
probe DiO. Arrows point to microstructural features of high probe density. The initial, 
polydisperse microbubble suspensions (A, B) are shown for comparison to the isolated 4–5 






Figure 2.5. Dot plots of side scatter (SSC) versus forward scatter (FSC) for polydisperse 
and size-isolated microbubbles as determined by flow cytometry. (A) shows the serpentine 
trend for the initial polydisperse microbubble suspension (cytometer settings: detector P1, 
voltage E01, amp 1.98; detector P2, voltage 287, amp 1.49). (B) shows no serpentine trend 
for the isolated 4–5 µm microbubbles (cytometer settings: detector P1, voltage E01, amp 
2.30; detector P2, voltage 173, amp 2.88). 
The origins of polydispersity in the freshly generated suspension of lipid-coated microbubbles 
observed here may be explained by the multiple interacting mechanisms occurring during 
entrainment and cavitation-induced disintegration, as described above.  The fact that the 




adds further complexity to analysis.  Additionally, the dynamics of lipid adsorption and 
spreading and monolayer shell formation are expected to play a role in determining the apparent 
surface tension and, for the lipids used here, may be expected to add additional surface viscosity 
and elasticity terms.  Marangoni effects are expected to play a central role in both entrainment 
and cavitation-induced breakdown (Edwards, Brenner et al. 1991).  While polydispersity may be 
unavoidable, the ability of mechanical agitation to rapidly generate large numbers of 
microbubbles brings this technique to the forefront of current microbubble creation methods.  
Given the excellent stability of lipid-coated microbubbles and the apparent presence of distinct 
peaks in the multimodal distribution, size isolation by differential centrifugation appeared to be a 
feasible approach.  In what follows, we describe experiments set at isolating narrow distributions 
and characterizing their size distribution and long-term stability. 
 
2.4.2. Size Isolation of Microbubbles 
Experiments were performed to isolate relevant subpopulations of the multimodal distribution 
and reduce polydispersity.  Submicron microbubbles were found to be relatively unstable and 
therefore were not isolated.  Instead, microbubbles in the 1-2 µm and 4-5 µm diameter ranges 
were isolated.  These ranges are interesting for biomedical applications.  While both sizes are 
comparable to that of an erythrocyte, they may possibly yield different biodistributions, 
resonance frequencies, and acoustically induced bioeffects.  In general, the 1-2 µm microbubbles 





Microbubbles in the larger diameter range (4-5 µm) were isolated first, while the smaller 
microbubbles were saved for the subsequent isolation of the 1-2 µm fraction.  After repeated 
centrifugation and re-concentration according to the simple model, microbubbles with diameters 
of 4-5 µm were successfully isolated from the initial polydisperse suspension (Fig. 2.6).  
Multiple centrifugation steps were needed to expel smaller microbubbles (< 4 µm), which were 
more abundant in the initial suspension.  The final 4-5 µm microbubble suspension typically had 
a total volume of 1 mL with concentration in the order of 108 to 109 mL-1, as determined by the 
Accusizer.  Table 2.1 summarizes both averaged number-weighted and volume-weighted mean 







Figure 2.6. Size distributions for initial polydisperse and final size-isolated microbubbles. 
Shown are isolated subpopulations at the 1–2 µm (A, B) and 4–5 µm (C, D) diameter size 
ranges. Comparison of number-weighted (A, C) and volume-weighted (B, D) size 

















(Mean ± SD) (Median ± SD) (Mean ± SD) (Median ± SD) 
Initial 1.35E+10 2.1 ± 0.5 1.4 ± 0.6 19.4 ± 17.1 19.0 ± 17.3 10.5 ± 10.6 
1-2 um 
Isolated 2.8E+09 1.3 ± 0.2 1.3 ± 0.2 1.8 ± 0.1 1.5 ± 0.2 1.5 ± 0.2 
4-5 um 
Isolated 1.01E+08 2.8 ± 0.2 3.0 ± 0.2 4.2 ± 0.1 4.1 ± 0.1 1.5 ± 0.1 
 
 Microbubbles of 1-2 µm diameter were isolated in fewer steps than for the 4-5 µm 
microbubbles.  For instance, separation of microbubbles less than 2 µm diameter in the 
infranatant was typically completed by a single centrifugation step.  However, the final step of 
concentrating microbubbles greater than 1-µm diameter required substantially higher centrifugal 
force than for the 4-5 µm microbubbles, which is consistent with their lower buoyancy.  The 
final 1-2 µm microbubble suspension typically had a total volume of 1 mL with concentration on 
the order of 109 to 1010 mL-1, as determined by the Accusizer.  
In order to assess size uniformity, we defined the polydispersity index (PI) as the volume-
weighted mean diameter divided by the number-weighted mean diameter. Table 2.1 gives the 
average PI value for the freshly generated microbubbles and the size-isolated microbubbles.  The 
initial suspension was highly polydisperse, with PI values as high as 18 but no lower than 6.  The 
PI for the 4-5 µm fraction was only 1.5 ± 0.1 (p < 0.05), while that of the 1-2 µm fraction was 
only 1.5 ± 0.2 (p < 0.05). 
Bright-field and epi-fluorescence microscopy images provided direct visual confirmation for the 




images using ImageJ gave mean diameters of 4.6 ± 0.3 µm and 1.8 ± 0.3 µm for microbubbles 
seen in Figs. 2.4C and 2.4E, respectively.  These results are in agreement with the size 
distributions determined by the Accusizer and Multisizer.  Fluorescence images also showed 
microstructural features within the lipid shell.  For example, brighter spots indicating non-
uniform DiO distribution were often observed (see arrows in Figures 2.4D and 2.4F).  Previous 
results have shown heterogeneous membrane probe distribution that indicated lateral phase 
separation (Borden, Pu et al. 2004; Borden, Martinez et al. 2006) and collapse in the lipid shell 
(Borden, Kruse et al. 2005; Pu, Borden et al. 2006). 
Flow cytometry was performed to characterize the size-isolated fractions (Fig. 2.7).  
Fluorescence intensity (FL), FSC and SSC measurements were all taken under the same 
cytometer settings.  The serpentine shape was not observed for the size-isolated suspensions, as it 
was for the polydisperse case.  Instead, the data points were found to be clustered in one region 
of the dot plot.  The lack of the serpentine shape in the size-isolated samples indicated that they 
were indeed subpopulations of the initial multimodal sample.  Table 2.2 lists the median values 
of three cytometry tests for each microbubble sample.  Comparison of the FSC and SSC results 
for individual, size-isolated fractions and their mixture supported the existence of two distinct 
microbubble subpopulations.  Monomodal distributions were observed for the individual size-
isolated suspensions, with a lower median value corresponding to the 1-2 µm microbubbles.  
When the size-isolated microbubbles were subsequently mixed together, a bimodal distribution 
appeared with two distinct peaks that agreed with the respective median values for the individual 
suspensions. 
As expected, a single peak was observed on the FL histogram for the size isolated microbubbles 




microbubbles.    Upon mixing, a bimodal distribution was observed with peak median FL values 
corresponding to those of the individual suspensions.  Assuming that each microbubble is a 
perfect sphere and the fraction of fluorophores in the lipid shell is the same for all microbubbles, 
regardless of size, the number of fluorophores per microbubble should be directly proportional to 
the surface area, or the square of the diameter.  This was confirmed when comparing the 
averaged FL values versus microbubble squared diameter.  The fluorescence intensity value for 
the mixture of 1-2 µm and 4-5 µm microbubble samples (775 ± 18) agreed with the average 
between the FL values measured for each individual monodisperse suspension (510 ± 16 and 







Figure 2.7. Fluorescence intensity and light scattering profiles for microbubble suspensions 
after size isolation as determined by flow cytometry. Three different tests (fluorescence 
intensity FL, forward- (FSC) and side- (SSC) light scattering versus particle count) were 
performed for the same sample as represented by each column of plots. Column 1 (A, D, G) 
and Column 2 (B, E, H) samples had median volume-weighted diameters of 1.8 and 4.6 µm, 
respectively. Column 3 (C, F, I) was a mixture of these two suspensions. Results are 










(Median ± SD) 
Forward-Light 
Scattering 
(Median ± SD) 
Side-Light 
Scattering 
(Median ± SD) 
1 - 2 µm 509.54 ± 16.02 137.00 ± 5.29 289.33 ± 4.93 
4 - 5 µm 1114.33 ± 35.03 214.33 ± 7.37 417.33 ± 23.50 
Mixture 775.17 ± 17.51 193.67 ± 0.58 375.67 ± 1.53 
 
Results from particle sizing, microscopy and flow cytometry showed the ability to isolate distinct 
fractions of the microbubbles at the desired size ranges.  Next, we determined how stable these 
size-isolated suspensions were when stored in the refrigerator.  What follows is an analysis of the 
shelf-life for size-isolated microbubbles. 
 
2.4.3. Stability of Size-Isolated Microbubbles 
For biomedical applications, it is desired that the microbubbles be stable for at least 48 
hours at their respective size distributions.  A test of microbubble stability was performed using 
samples concentrated to 1010 mL-1 for 1-2 µm microbubbles, and 108 mL-1 or 109 mL-1 for 4-5 µm 
microbubbles, in a 1-mL volume of 20 vol% glycerol in PBS and stored in a sealed 2-mL serum 
vial with PFB headspace (Fig. 2.8).  Table 2.3 shows the concentration and PI for the 1-2 and 4-5 
µm microbubbles at various time points following size isolation.  Both size fractions were stable 
over two days.  Microscopy after two days storage also indicated the persistence of intact 
microbubbles at their isolated size range over this timeframe.  However, results indicated that the 




concentration decreased from by an order of magnitude, and PI nearly doubled over a period of 
28 days.  For 4-5 µm microbubbles at less than 1 vol% encapsulated gas, the concentration 
decreased by more than half, and PI nearly doubled over a period of 14 days.  Higher 
microbubble concentrations provided much greater stability, as seen for the comparison of the 4-
5 µm microbubbles in Fig. 2.8.  In general, we found that encapsulated gas fractions greater than 
1 vol% were necessary for good stability, particularly when the vial is intermittently opened to 
the atmosphere as typically occurs for an in vivo study (data not shown). Interestingly, when 
measuring the number-weighted distribution with the Accusizer, the monomodal peak for the 4-5 
µm microbubbles changed to a bimodal peak during storage.  Figure 2.8C shows that 4-5 µm 
microbubbles degraded into 1-2 µm microbubbles as well as larger microbubbles over the test 
period.  The formation of the larger microbubbles is consistent with Ostwald ripening, in which 
small microbubbles shrink at the expense of larger ones (Taylor 1998), as a major factor 








Figure 2.8. Stability of size-isolated microbubbles. Shown are distributions at various time 
points for the 1–2 µm (A, B) and 4–5 µm (C, D, E, F) diameter microbubbles. Number-
weighted (A, C, E) and volume-weighted (B, D, F) distributions are shown for inspection of 
polydispersity. The suspensions initially were dispersed in 1-mL volume of PBS with 20 
vol% glycerol, with a concentration of ∼1010 mL−1 for the 1–2 µm diameter microbubbles 
and either <1 vol% (C, D) or >1 vol% (E, F) for the 4–5 µm diameter microbubbles. Each 
curve is the average of three experiments with three measurements each. Results are 























1-2 micron bubble stability  
Initial 2.3E+10 ± 1.4E+09 3.7 ± 0.4% 1.3 ± 0.1 1.2 ± 0.1 1.9 ± 0.1 1.8 ± 0.1 1.5 ± 0.1 
1 day 8.3E+09 ± 2.9E+09 1.1 ± 0.4% 1.2 ± 0.1 1.2 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 1.4 ± 0.1 
7 days 7.6E+09 ± 1.3E+09 1.0 ± 0.2% 1.3 ± 0.1 1.4 ± 0.1 1.8 ± 0.1 1.7 ± 0.1 1.4 ± 0.1 
14 days 4.3E+09 ± 4.2E+08 0.79 ± 0.09% 1.4 ± 0.1 1.4 ± 0.1 2.0 ± 0.1 1.7 ± 0.1 1.4 ± 0.1 
28 days 1.1E+09 ± 1.3E+08 0.39 ± 0.06% 1.5 ± 0.1 1.4 ± 0.1 4.1 ± 0.1 2.6 ± 0.1 2.8 ± 0.1 
 
4-5 micron bubble stability for suspensions containing less than 1% gas volume  
Initial 1.2E+08 ± 2.8E+07 0.34 ± 0.08% 3.2 ± 0.1 3.4 ± 0.1 4.8 ± 0.1 4.5 ± 0.1 1.5 ± 0.1 
2 days 1.0E+08 ± 2.5E+06 0.29 ± 0.01% 3.2 ± 0.1 3.4 ± 0.1 4.8 ± 0.1 4.4 ± 0.1 1.5 ± 0.1 
7 days 9.6E+07 ± 1.1E+06 0.28 ± 0.03% 3.1 ± 0.1 3.2 ± 0.1 5.3 ± 0.1 4.6 ± 0.1 1.7 ± 0.1 
14 days 3.9E+07 ± 8.6E+06 0.15 ± 0.02% 2.8 ± 0.1 2.1 ± 0.1 8.1 ± 0.1 7.6 ± 0.1 3.0 ± 0.1 
 
4-5 micron bubble stability on suspensions containing greater than 1% gas volume  
Initial 6.30E+08 ± 2.9E+07  1.9 ± 0.1% 3.3 ± 0.1 3.5 ± 0.1 4.9 ± 0.1 4.3 ± 0.1 1.5 ± 0.1 
7 days 5.01E+08 ± 4.6E+07 1.1 ± 0.1% 2.9 ± 0.1 2.9 ± 0.1 4.8 ± 0.3 4.1 ± 0.1 1.6 ± 0.1 





 The greater stability of 1-2 µm microbubble suspensions versus the 4-5 µm microbubble 
suspensions observed here could be explained by the higher concentration of microbubbles, 
which itself is a direct result of the more abundant population of the smaller microbubbles.  We 
found in general that more concentrated suspensions tended to be more stable, regardless of 
microbubble size.  This presumably was due to a thicker cake coating the top surface that 
buffered against film rupture and gas release at the surface (“popping”) that could diminish the 
population.  However, this does not explain the greater number of 1-2 µm microbubbles in the 
initial formulation, nor the observation that the 4-5 µm microbubbles broke down over time into 
1-2 µm microbubbles.  These two observations clearly point to greater stability for the 1-2 µm 
microbubbles in these formulations.  The presence of a stable microbubble size is not predicted 
by any current theory of microbubble stability.  Models that account for microbubble dissolution, 
such as Epstein and Plesset’s original formulation (Epstein and Plesset 1950), clearly indicate 
that smaller microbubbles should be less stable, due to higher curvature and surface-to-volume 
ratio.  Yet we observed microbubbles that were more stable at the smaller diameter!  This data 
correlates well with the stable diameter previously observed during acoustically driven 
dissolution (Borden, Kruse et al. 2005; Wrenn 2008), and also the stable diameter reached for 
lipid-coated microbubbles made via microfluidics (Talu, Hettiarachchi et al. 2008).  However, 
submicron bubbles were found to be less stable than 1-2 µm microbubbles, which indicated the 
existence of an optimal microbubble size. 
What could explain the presence of an optimally stable diameter for these lipid-coated 
microbubbles?  We speculate that the greater stability is due to microstructural features of the 
lipid shell and lipid aggregates present in the continuous phase.  Dressaire et al. recently 




between domain bending and pressure-volume work (i.e., Laplace overpressure) (Dressaire, Bee 
et al. 2008).  In their analysis, however, size was fixed by the blending conditions.  It may be that 
size was fixed here by cavitation during acoustic emulsification, according to Li and Fogler’s 
analysis (Li and Fogler 1978; Li and Fogler 1978).  However, this does not explain the same 
stable diameter observed by Talu et al. (Talu, Hettiarachchi et al. 2008) for microbubbles made 
by microfluidics, in which no cavitation shock waves were produced, nor does it explain the 
stability against acoustically driven dissolution at this size (Borden, Kruse et al. 2005).  Future 
work on the relationships between lipid nanostructural features and microbubble stability is 
clearly warranted to better explain this phenomenon. 
 
2.5.   Conclusions 
 Lipid-coated microbubbles formed by acoustic emulsification were found to be 
polydisperse and appeared to be multimodal, with distinct peaks centered near 1-2 and 4-5 µm 
diameter.  Differential centrifugation was used successfully to isolate narrowly dispersed 
fractions at these size ranges.  These size ranges are stable over a period of at least two days, 
although the 4-5 µm microbubbles were found to disintegrate into 1-2 µm microbubbles after 
two weeks.  This latter observation indicates a stable diameter in the 1-2 µm range for these 
microbubbles, which is supported by observations of microbubbles that underwent acoustically 
driven dissolution and those formed by microfluidics.  Overall, differential centrifugation 
appears to be a useful approach to generate narrow distributions at relevant sizes for biomedical 
applications and may lend itself to the study of the surface properties and colloidal behavior of 




Chapter 3. Theranostic Gd(III)-Lipid Microbubbles for MRI-Guided Focused 
Ultrasound Surgery 
3.1. Introduction 
MRI-guided focused ultrasound therapy is a rapidly developing medical technique that 
utilizes high intensity focused ultrasound (FUS) to ablate tissue and MRI to monitor the applied 
thermal dosage (Cline, Schenck et al. 1992; Hynynen, Darkazanli et al. 1993; Jolesz and 
McDannold 2008).  MRI-guided FUS therapy is approved by the US Food and Drug 
Administration for the treatment of uterine fibroids, and it is currently being developed to treat 
liver, bone, prostrate and brain-related diseases (Hudson and Stewart 2008; Jolesz and 
McDannold 2008; Jolesz 2009).  At high acoustic intensities, gas-filled microbubbles (MBs) may 
form and undergo inertial cavitation, producing jets and shockwaves that enhance the heating of 
tissue.  However, the formation of these inception microbubbles is unpredictable, and their 
cavitation can result in tissue damage outside of the desired target region.  Pre-formed 
microbubbles, which are currently FDA-approved as intravascular contrast agents for 
echocardiography, can be used as cavitation nuclei to lower the acoustic intensity threshold 
required for tissue ablation with FUS, thereby lowering the thermal buildup in surrounding tissue 
(Tran, Seo et al. 2003; Kaneko, Maruyama et al. 2005; Tung, Liu et al. 2006; Yu, Hu et al. 
2008).  Intravenously administered microbubbles also may be used to enhance vascular 
permeability for targeted drug and gene delivery (Unger, Porter et al. 2004; Ferrara, Pollard et al. 
2007).  For example, microbubbles have been used to lower the acoustic intensity threshold 
needed for FUS-induced blood-brain barrier (BBB) opening (Hynynen, McDannold et al. 2001; 




detectable microbubble formulation, which could be used to measure microbubble concentration, 
image cavitation events and determine the biodistribution of microbubble shell debris (a potential 
surrogate for an attached drug) following FUS.  Such microbubbles may also be useful as general 
dual modality US/MRI contrast agents. 
Previously, microbubbles were demonstrated to enhance the T2*-weighted MRI contrast 
in vivo by virtue of the change in magnetic susceptibility at the gas-liquid interface (Wong, 
Huang et al. 2004; Cheung, Chow et al. 2009).  This negative enhancement was reportedly a 
linear function of gas concentration and was further increased in subsequent studies by loading 
T2-weighted MRI contrast agents (iron oxide particles) onto the shell of polymeric microbubbles 
(Chow, Chan et al. ; Yang, Li et al. 2008; Yang, Li et al. 2009).  Recently, Lui et al. (Liu, 
Lammers et al. 2011) reported that ultrasonic fragmentation of magnetite-loaded polymeric 
microbubbles resulted in greater proton relaxation than for the intact microbubbles.  This effect 
was attributed to the greater interaction of peripheral water to released iron oxide particles.  
These superparamagnetic microbubbles offer significant potential as theranostic agents for MRI-
guided FUS. 
An alternative means to produce dual modality US/MRI contrast agents is to load 
microbubbles with paramagnetic contrast agents, such as gadolinium ions.  Gd(III) enhances the 
positive contrast of blood by shortening both the longitudinal and transverse proton relaxation 
times, T1 and T2 (Caravan, Ellison et al. 1999; Aime, Botta et al. 2005; Hermann, Kotek et al. 
2008).  Previously, Gd(III)-DTPA was loaded into the shell of 1.5-µm diameter polymeric 
microbubbles (Ao, Wang et al. 2010).  The enhancement of the T1-weighted MRI signal was 
reportedly a linear function of Gd(III)-DTPA-loaded microbubble concentration.  However, 




echogenicity for ultrasound imaging and requiring greater acoustic intensity to induce 
microbubble fragmentation and sonoporation for therapy (Hoff, Sontum et al. 2000; Bloch, Wan 
et al. 2004). 
Lipid-coated microbubbles with Gd(III)-bound shells have not been reported in literature 
previously.  However, Gd(III)-bound liposomes have been designed and characterized as T1-
weighted MRI contrast agents for applications in cellular and small animal imaging (Ghaghada, 
Hawley et al. 2008; Terreno, Castelli et al. 2008; Ghaghada, Ravoori et al. 2009; Hak, Sanders et 
al. 2009; Kamaly, Kalber et al. 2010).  Liposomes and lipid-coated microbubbles are similar with 
respect to their lipid composition and formulation (Ferrara, Borden et al. 2009).  The main 
difference between the two is that microbubbles consist of a condensed monolayer with a gas 
core and are typically a few microns in size, while liposomes consist of a lipid bilayer with an 
aqueous core and are usually several hundred nanometers in size.  Gd(III) can be loaded into the 
liposomal aqueous core and/or conjugated to the lipid polar headgroups in the bilayer 
(Ghaghada, Hawley et al. 2008; Ghaghada, Ravoori et al. 2009; Hak, Sanders et al. 2009).  
While both strategies were reported to increase the T1-weighted MRI relaxation rate, surface 
conjugation resulted in greater relaxation enhancement than encapsulation, owing to greater 
access of bulk water protons to the Gd(III) ions (Ghaghada, Ravoori et al. 2009).    Owing to the 
presence of the gas core and thin monolayer shell, lipid-coated microbubbles can only be 
functionalized with Gd(III) ions using a surface conjugation methodology.  Since the lipid 
coating of microbubble shells self-assembles into liposomal bilayers in the absence of the gas 
core, a comparison of the MRI relaxation rates of Gd(III)-bound microbubbles before and after 




Below, we report the fabrication and characterization of lipid-coated microbubbles that 
were surface-conjugated with the paramagnetic MRI contrast agent, Gd(III).  Gadolinium was 
selected over iron oxide since it works primarily to enhance positive contrast through increasing 
longitudinal proton relaxation (Caravan, Ellison et al. 1999).  The chelation ligand DOTA was 
chosen over DTPA since it forms a more thermodynamically stable complex with Gd(III) (De 
Leon-Rodriguez and Kovacs 2008).  A stronger chelator is preferred since free Gd(III) ions in 
vivo have been associated with nephrogenic systemic fibrosis (Sherry, Caravan et al. 2009).  
Additionally, the 4-5 µm microbubble size range was selected because of its increased acoustic 
signal and circulation persistence (Sirsi, Feshitan et al. 2010; Streeter, Gessner et al. 2010) and 
more effective BBB opening capability compared to polydisperse and smaller size-ranged 
microbubbles (Choi, Feshitan et al. ; Tung, Marquet et al. 2011).  The resulting microbubbles 
were tested for ultrasound contrast in vivo and MRI contrast in vitro. Finally, we report both 
longitudinal (R1 = 1/T1) and transverse (R2 = 1/T2) relaxation rates of the Gd(III)-bound 
microbubbles before and after they were fragmented into lipid bilayers by sonication.   
 
3.2. Materials and Methods  
3.2.1. Materials 
All solutions were prepared using filtered, 18 MΩ-cm deionized water (Direct-Q, Millipore, 
Billerica, MA).  Glassware was cleaned with 70 vol% ethyl alcohol solution (Sigma-Aldrich; St. 
Louis, MO) and rinsed with deionized water.  The gas used to form microbubbles was 
perfluorobutane (PFB) at 99 wt% purity obtained from FluoroMed (Round Rock, TX).  1,2-




(Alabaster, AL). 1,2-distearyol-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)2000] (DSPE-PEG(2000)) was obtained from NOF America Corporation (White Plains, 
NY).  5/6-carboxyfluorescein succinimidyl ester (FITC-NHS) was purchased from Pierce 
(Rockford, IL).  1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-
hydroxysuccinimide ester) (DOTA-NHS) was purchased from Macrocyclics (Dallas, TX) and 
dissolved in N,N-dimethylformamide (DMF; Sigma-Aldrich) prior to use.  Gadolinium (III) 
chloride (GdCl3) was purchased from Sigma Aldrich and dissolved in 0.2 M, pH 5.6 acetate 
buffer (VWR, Radnor, PA). 
 
3.2.2.  Microbubble Generation and Size Isolation 
Microbubbles were formulated using a lipid suspension of 90 mol% DSPE and 10 mol% DSPE-
PEG(2000) at 2 mg/mL in 100 mL PBS (pH 7.2; 0.15 M NaCL, 0.2 M phosphate).  The solution 
was degassed by applying house vacuum with constant stirring.  The solution was then preheated 
to 80 oC, which is 6 oC above the main phase transition temperature (Tm) of DSPE (Cevc and 
Marsh 1985).  The lipid mixture was sonicated with a 20-kHz probe (model 250A, Branson 
Ultrasonics; Danbury, CT) at low power (3 watts) in order to further disperse the lipid aggregates 
into small, unilamellar liposomes.  PFB gas was introduced by flowing it over the surface of the 
lipid suspension.  Higher power sonication (33 watts) was applied to the suspension for about 10 
seconds at the gas-liquid interface to generate microbubbles. 
The microbubble suspension was collected into 30 mL syringes (Tyco Healthcare, Mansfield, 
MA), which were used as the flotation columns.  Washing and size-selection by centrifugation 




Centrifugation at 300 RCF (relative centrifugal force) for 5 min was performed to collect all 
microbubbles from the suspension into a cake resting against the syringe plunger.  The remaining 
suspension (infranatant), which contained residual lipids and vesicles, was recycled to produce 
the next batch of microbubbles.  All resulting cakes were combined and re-suspended in PBS to 
improve total yield. 
Microbubble size distribution was determined by laser light obscuration and scattering 
(Accusizer 280A, NICOMP Particle Sizing Systems, Santa Barbara, CA).  During 
measurements, 2 µL samples of each microbubble suspension were diluted into a flask 
containing 30 mL of distilled water under mild mixing.  All samples were measured in triplicate 
and analyzed for both number- and volume-weighted size distributions.  The 4-5 µm size class 
was isolated as described in chapter 2 and reconstituted in pH 8.5 PBS. 
 
3.2.3. Synthesis of Gd(III)-bound Microbubbles 
Microbubbles with Gd(III)-bound shells were fabricated using a post-labeling technique (Chen 
and Borden 2010; Chen and Borden 2011). The macrocyclic ligand DOTA-NHS was conjugated 
to the amine group of the DSPE in the shell of size-selected microbubbles, followed by chelation 
of Gd(III).  The NHS ester contains an electrophilic active group that couples rapidly with the 
primary amine on DSPE to create a stable amide bond.  Figure 3.1 shows a schematic of the 





Figure 3.1. Synthesis of the Gd(III)-DOTA-DSPE microbubble shells using the post-
labeling technique: (i) 100 M excess DOTA-NHS, pH 8.5; (ii) 20 M excess GdCl3, pH 5.6, T 
= 50 or 70 oC; (iii) storage at pH 7.4. 
 
3.2.4. Surface Functionalization with FITC-NHS or DOTA-NHS 
Each 4-5 µm microbubble sample was diluted to 2 x 109 MB/mL using pH 8.5 PBS.  Following 
Chen and Borden, the total amount of available functional lipid groups (DSPE) on the 
microbubble surface was calculated assuming that the microbubbles were spherical with an 
average molecular area of 0.4 nm2.  To test the post-labeling headgroup conjugation method, 
FITC-NHS was added to a 100:1 molar ratio of NHS to amine, and the mixture was continually 
stirred at room temperature for 2 hours using a benchtop rotary mixer.  To chelate Gd(III), 




as above.  Unreacted FITC-NHS or DOTA-NHS was removed by several cycles of flotation 
using 0.2 M, pH 5.6 acetate buffer.  The microbubble cake was then analyzed for size with the 
Accusizer.      
 
3.2.5.  Complexation of Gd(III) to DOTA on Microbubble Shells 
Based on the initial concentration and size distribution calculated from the Accusizer, each 
sample of DOTA-bound microbubbles was diluted to at least 2 x 109 MB/mL using pH 5.6 
acetate buffer.  Assuming 100% binding of DOTA to available functional DSPE lipid groups, the 
amount of GdCl3 needed for a 20:1 molar ratio of Gd(III) to DOTA was determined and mixed 
with the microbubble suspension.  The sample mixture was sealed in a 3 mL serum vial then 
immersed under continuous stirring in a water bath whose temperature was controlled at 50 oC or 
70 oC for 2 hours.  After reaction, the sample mixture was cooled to room temperature by 
running the vial under cold tap water for 10 min.  Excess Gd(III) ions were removed by several 
cycles of washing/centrifuging (1 minute, 100 RCF) using pH 5.6 acetate buffer followed by 
several cycles of washing/centrifuging using pH 7.4 PBS as solvent medium.  The final 
microbubble cake was reconstituted to a volume of 1 mL and a concentration of at least 1 x 109 
MB/mL using pH 7.4 PBS.  The size distribution and concentration of microbubbles after 
chelation reaction were determined by the Accusizer.  The concentration of Gd(III)-bound to the 
microbubble shell was determined by inductively coupled plasma optical emission spectroscopy 
(ICP-OES, ACTIVA, HORIBA, Edison, NJ).  Destruction/fragmentation of microbubbles in 





3.2.6. Ultrasound Characterization of Gd(III)-bound Microbubbles 
All animal experiments were conducted according to the National Institutes of Health guidelines 
and approved by the University of Colorado Institutional Animal Care and Use Committee.  
Ultrasound imaging was performed using a high-frequency ultrasound scanner (Vevo 2100, 
Visualsonics, Toronto, Ontario, Canada) with a MS-250 transducer.  Images were acquired using 
the contrast mode setting at 18 MHz transmit frequency and 4 % power.  The transducer was 
positioned at the mouse midsection along the long axis of the kidney.  B-mode ultrasound images 
were acquired using a field of view of 13 x 16 mm2.  Mice were anesthetized with 3 % isoflurane 
and tail veins were catheterized for injections, as previously described (Sirsi, Feshitan et al. 
2010).  A 100-µL bolus (1 x 108 MB/mL) followed by a 15-µL saline flush was injected while 
imaging at the maximum frame rate for respiratory gating (~14 frames/second).  B-mode images 
captured before and after microbubble injection were used to detect signal enhancement using a 
background reference subtraction method.  
 
3.2.7. MRI Characterization of Gd(III)-bound Microbubbles 
The effect of Gd(III)-bound microbubbles on the T1 and T2 relaxation times was determined 
using MRI relaxometry.  Intact and fragmented Gd(III)-bound microbubbles were mixed with 
saline in four different volume ratios (0, 25, 50 and 100%) creating 200 µL solutions, which were 
placed in MR-compatible tubes with an inner diameter of 5 mm.  Intact and fragmented 4-5 µm 
DOTA-bound microbubbles without Gd(III) binding were used as controls.  A 9.4 T vertical 
MRI system (Bruker Biospin, Billerica, MA) was used to acquire turbo spin echo (RARE-VTR) 




(MSME) images with variable echo times (from 20 to 320 ms) for T1 and T2 mapping, 
respectively.  This spin-echo sequence reportedly lacks sensitivity to inhomogeneities in the 
magnetic field compared to gradient-echo sequences used in susceptibility-weighted imaging of 
microbubbles (Berns, Ross et al. 1991; Cheung, Chow et al. 2009).  Eight 1.5 mm-thick, axial 
slices with a field of view (FOV) of 15×15 mm2 (matrix size: 96×96) covered the entire solution 
in each tube.  Each slice depicted a slab of all four solutions at a specific height.  T1 and T2 
relaxation maps of each slice were derived using the Image Processing Toolbox of MATLAB 
R2008b (MathWorks Inc., Natick, MA).  The first and last slice were not taken into account in 
the relaxation measurements, since the MR signal coming from these slices was contaminated by 
the void below and over the solution.  The pixel-by-pixel estimations were used to generate T1 
and T2 maps.  Four pre-defined, identical, circular regions of interest (ROI) of 2.35 mm in 
diameter were selected on each slice, in order to measure the relaxation rate of each solution 
throughout the tube.  Each ROI covered a large surface area within the limits of the tube. Six 
measurements were made for each tube (from slice 1 to 6) and the mean value yielded the T1 or 
T2 relaxation times for each solution.  Molar relaxivities (r1 and r2) were calculated from slopes 
of regression lines of the plot of R1 and R2 versus Gd(III) concentration. A two-tailed unpaired 
student t-test was used to determine the significance between r1 and r2 of fragmented versus 









3.3.1. Preparation of Gd(III)-bound Microbubbles 
The size isolation protocol yielded 4-5 µm diameter microbubbles at a concentration a least 2 x 
109 MB/mL.  Figure 3.2 shows visual confirmation of FITC-NHS coupling to the DSPE shell 
using epi-fluorescence microscopy.  The fluorescence intensity level was not uniform across 
individual microbubble, which suggested a heterogeneous coverage of FITC on lipid monolayer.  
However, this result confirmed that small molecules (< 1 kDa) could diffuse through the PEG 
brush layer to react with the polar lipid headgroups.  This is an extension of previous post-
labeling work, which showed reactions occurring on PEG-tethered active groups (Klibanov 
2005; Chen and Borden 2010; Chen and Borden 2011), but not with the underlying lipid.  
 
Figure 3.2. Fluorescence microscopy image of 4-5 µm DSPE-coated microbubbles modified 




Figure 3.3 shows the change in size distribution of microbubbles before and after conjugation of 
DOTA (at room temperature) to the primary amines on the DSPE shell via NHS coupling.  After 
DOTA conjugation, microbubble concentration and number-weighted median diameter deviated 
by less than 1%.  Thus, the DOTA reaction did not appear to increase the lipid headgroup area 
sufficiently to affect lipid packing and thereby change microbubble size or stability. We did not 
detect Gd(III) binding to DOTA-microbubbles after incubation at room temperature for several 
hours (data not shown).  The Gd(III)-DOTA complex has been reported to take several days to 
complete at room temperature (De Leon-Rodriguez and Kovacs 2008).  This is because the rate-
determining step involves the slow, base-assisted rearrangement and deprotonation of an 
intermediate before formation of the final complex (Sherry, Caravan et al. 2009).  Previous 
researchers have completed the Gd(III)-DOTA chelation reaction in 5 min by heating reactants 
to 90 oC, or in 20 min by heating to 80 oC (De Leon-Rodriguez and Kovacs 2008).  However, 
these temperatures are above the main phase transition temperature (Tm) of the lipid component 
DSPE (74 oC) and may have resulted in significant microbubble destabilization.  We therefore 







Figure 3.3. Number-weighted size distributions of DSPE microbubbles before and after 
conjugation with DOTA-NHS. 
Figure 3.4 shows the change in size distribution of microbubbles before and after chelation of 
Gd(III) under these conditions.  After chelation at 50 oC, microbubble concentration decreased 
by ~50% while the number-weighted median diameter deviated by less than 1%.  After chelation 
at 70 oC, however, microbubble concentration decreased by ~65% while the number-weighted 
median diameter also decreased by ~30%.  From ICP-OES analysis, the Gd(III) chelation on the 
microbubble shell occurring at 70 oC and 50 oC was 7.0 x 105 ± 1.6 x 105 (mean ± standard 
deviation) and 7.5 x 105 ± 3.0 x 105 ions/µm2, respectively.  Therefore, all subsequent chelation 
reactions were carried out at 50 oC since the size distribution of microbubbles was maintained at 
this temperature without affecting the degree of Gd(III) binding.  Under these conditions, the 
average Gd(III) loading was 3.6 x 107 ± 1.0 x 107 ions/microbubble.  ICP-OES analysis also 
determined that negligible amounts of Gd(III) bound to lipid-coated microbubbles without 






Figure 3.4. Number-weighted size distributions of microbubbles before and after Gd(III) 
chelation at A) 50 oC and B) 70 oC. 
Thus, the post-labeling methodology provided a robust means of generating size-selected, Gd-
DOTA-lipid microbubbles.  Previous work showed that small molecules are capable of diffusing 
through a PEG overbrush on the microbubble surface to bind to functional groups tethered by 
shorter PEG chains (Chen and Borden 2010; Chen and Borden 2011).  Here, we showed that the 
small molecule DOTA-NHS is capable of diffusing through the PEG brush to bind to a 
functional amine on the lipid headgroup.  The average molecular area was ~1-2 nm2 per Gd-
DOTA complex.  This value was higher than that of the minimum molecular area for a lipid 
(~0.4 nm2), indicating that roughly 20-40% of the DSPE was conjugated to Gd-DOTA.  This 
fraction is similar to previous reports for Gd-DOTA-DSPE liposomes (Hak, Sanders et al. 2009) 




3.3.2.  Ultrasound Characterization of Gd(III)-microbubbles 
Lipid-coated microbubbles labeled with Gd(III) were tested for echogenicity in the mouse kidney 
using a preclinical ultrasound scanner.  Figure 3.5 shows the B-mode images before and after 
microbubble injection.  A bolus injection of 1 x 107 Gd(III)-bound microbubbles significantly 
increased the fundamental mode backscatter, as was evident by an increase in video intensity and 
speckling throughout the kidney region.  Higher microbubble doses (e.g., 5 x 108) led to strong 
contrast enhancement in the upper portion of the kidney and shadowing in the lower portion 
(data not shown).  These results show that the Gd(III)-bound microbubbles are highly echogenic 
and suitable for contrast-enhanced US imaging. 
 
 
Figure 3.5. Ultrasound images of the mouse kidney before and after bolus injection of 1 x 
107 Gd(III)-bound microbubbles: (Left) pre-injection, (Middle) post-injection, (Right) 







3.3.3. MRI Characterization of Gd(III)-microbubbles  
Figures 3.6a and 3.6b show the T1-weighted and T2-weighted MRI maps of fragmented and 
intact Gd(III)-bound and control (DOTA without Gd(III)) microbubbles.  Fragmented 
microbubbles were produced by the removal of the gas core of intact microbubbles through bath 
sonication and heating.  The color-coding (from red to blue) indicates a greater relaxation effect 
and therefore an MRI signal intensity increase.  Figures 3.7a-d show plots of the longitudinal and 
transversal relaxation rates (R1 and R2) of intact and fragmented Gd(III)-bound microbubbles as 
a function of microbubble concentration, normalized to total Gd(III) concentration using ICP-
OES results, for 4 independent trials.  Results also are shown for intact and fragmented control 
microbubbles as a function of surface area. 
   
3.3.4.  Relaxation Rates of Control Microbubbles and their Fragments 
As observed from both the T1- and T2-weighted color-coded MRI maps (Fig. 3.6), the control 
microbubbles (DOTA without Gd(III)) produced an MRI signal similar to baseline (saline), 
which did not deviate significantly with an increase in microbubble concentration.  This is 
further evident in the plot of the relaxation rate versus increasing microbubble surface area for 
both R1 and R2 (Fig. 3.7a,b).  The lack of a significant relaxation effect was found for both intact 







3.3.5.  Relaxation Rates of Gd(III)-bound Microbubbles and their Fragments 
Figure 3.6 also shows that the intact Gd(III)-bound samples produced similar MR signal 
intensities as saline and control microbubbles, and the signal intensity was not dependent on an 
increase in sample concentration.  Similarly, Figures 3.7c and 3.7d show that the relaxation rate 
did not increase with increasing intact Gd(III)-bound microbubble concentration (the fitted slope 
was slightly negative); the MRI signal was similar to that of control samples.  This was 
surprising, as we expected the MRI signal to increase with increasing Gd(III) as has been 
observed in liposomal suspensions (Ghaghada, Hawley et al. 2008; Terreno, Castelli et al. 2008; 
Ghaghada, Ravoori et al. 2009; Hak, Sanders et al. 2009; Kamaly, Kalber et al. 2010). 
Interestingly, the fragmented Gd(III)-bound microbubbles resulted in a noticeable increase in 
color-coded MRI signal intensity compared to saline, control and intact Gd(III)-bound 
microbubbles (Figs. 3.6 and 3.7).  Additionally, the effect was concentration-dependent, with an 
increase in fragmented Gd(III)-bound sample concentration leading to an increase in MRI signal 
intensity.   These results suggest that the MR signal came primarily from the Gd(III) groups and 
not the other components of the lipid microbubble shell, and the relaxation rate appeared to be 











Figure 3.6. Color maps of MRI relaxation time for intact and fragmented microbubble 
samples. Longitudinal relaxation time (A) and transverse relaxation time (B) increases 
from blue to red, as shown. Samples are arranged shown: row 1) intact DOTA-bound 
control microbubbles; 2) fragmented DOTA-bound control microbubbles; row 3) intact 
Gd(III)-bound microbubbles; row 4) fragmented Gd(III)-bound microbubbles. Students t-
tests showed that, for a given microbubble sample, T1 and T2 were not statistically different 





Figure 3.7. Relaxation rates of intact and fragmented microbubble samples. A) R1 versus 
MB surface area; B) R2 versus MB surface area; C) R1 versus Gd(III) concentration; D) R2 
versus Gd(III) concentration.  
3.3.6.  Molar Relaxivities of Gd(III)-bound Microbubbles 
Molar relaxivities (mM-1s-1) were calculated from the slopes of the linear trendlines in Figures 
3.7c and 3.7d and are shown in Table 3.1.  Fragmentation of the intact Gd(III)-bound 
microbubble samples led to a 40-fold increase in longitudinal molar relaxivities r1 (p < 0.05) and 
a 32-fold increase in transverse molar relaxivities r2 (p < 0.05).  Thus, both r1 and r2 for the 




intact Gd(III)-bound microbubbles.  A potential mechanism for this surprising phenomenon is 
discussed below. 
 
Table 3.1: Relaxivity of Intact and Fragmented Gd(III)-bound Microbubbles 
 





Intact MBs -0.1 ± 0.10 3.8 ± 5.8 -3.6 x 106 1.4 x 108 




The relaxivity values in table 3.1 were determined from the quantifying the relative changes in 
signal intensity from MRI images.  This relaxivity values do not necessarily represent actual 
theoretical values based on relaxation theory.  This is because the MRI protocol used is designed 
primarily for making qualitative comparisons between images whose quality may change 
depending on machine sensitivity.  One way to determine accurate values of relaxivity would be 
to employ standardized techniques like Nuclear magnetic resonance (NMR) spectroscopy.  
Surprisingly, we found that the relaxivity of Gd(III)-lipid monolayer-coated microbubbles 
increased significantly after destruction by sonication to form bilayer fragments.  One 
explanation is that the presence of the microbubble gas core weakened the MRI signal intensity 
owing to susceptibility effects.  However, the small difference in relaxation rates between intact 




samples (Fig. 3.7), does not support this explanation.  We propose an alternative explanation for 
this phenomenon based on the difference in bulk water access to the Gd(III)-DOTA-DSPE 
complex for microbubbles versus liposomes (Fig. 3.8).  Gd(III) is a paramagnetic ion that must 
interact with and exchange nearby water protons via its inner core (first hydration layer) in order 
to have a measurable effect on relaxivity (Toth, Helm et al. 2002).  Intact microbubbles, which 
comprise a highly condensed monolayer shell held under compression by Laplace pressure-
driven dissolution (Kim, Costello et al. 2003; Duncan and Needham 2004), may have restricted 
access of aqueous protons to the Gd(III) ion.  Fragmentation of the microbubble converted the 
lipid to a more relaxed liposomal bilayer configuration, which may have allowed for greater 
access of water molecules to the Gd(III) complex, thus allowing a greater relaxation 
enhancement.  The average area per lipid molecule for a fully compressed monolayer may be as 
low as 0.32 nm2 (Saad, Policova et al. 2009), which is 25 % less than that for a typical gel-phase 
bilayer of 0.48 nm2 (Lewis and Engelman 1983; Israelachvili 1992; Nagle and Tristram-Nagle 
2000; Petrache, Dodd et al. 2000).  We therefore propose that the tighter lipid packing in the 
monolayer configuration silences the relaxation effect by inhibiting water proton exchange 
between the Gd(III) complex and the bulk, whereas looser packing in the bilayer configuration 
provides sufficient exchange to significantly affect relaxation.  This mechanism is supported by 
recent results for magnetite-bearing polymeric microbubbles, in which a rise in longitudinal and 
transversal relaxivities was found following microbubble destruction and release of the iron 





Figure 3.8. Cartoon showing proposed mechanism for MRI relaxivity increase with the 
cavitation-induced conversion of lipid from the compressed monolayer form on the intact 
microbubble to the relaxed bilayer form of the fragments. The lipid molecular area and 
hydrocarbon membrane thickness are estimated to be 0.32 nm2 and 2.2 nm for the 
condensed monolayer (Saad, Policova et al. 2009; Israelachvili 2011) and 0.48 nm2 and 2.4 
nm for the relaxed, gel-state bilayer (Lewis and Engelman 1983; Nagle and Tristram-Nagle 
2000; Petrache, Dodd et al. 2000; Israelachvili 2011). The parameters shown in the 
schematic are the outer hydration shell of the Gd(III) ion, OS; the inner hydration shell, 
IS; the molecular tumbling time, τR; and the proton exchange rate from the OS to the IS, 
kex. It is proposed that the ability of the Gd(III) ion to magnetize bulk water protons, i.e., 





Regardless of the underlying mechanism, this behavior of Gd(III)-bound microbubbles may have 
useful implications for MRI-guided FUS therapy.  Using the Gd(III)-bound microbubbles 
fabricated here, one may envision that microbubble cavitation within the ultrasound focus can be 
spatially and temporally controlled in situ via monitoring of the MRI signal increase as the 
Gd(III)-DOTA-DSPE is converted from monolayer to bilayer.  Cavitation detection during 
focused ultrasound surgery may serve as a method to guide and monitor therapeutic effects and 
prevent unwanted bioeffects (Farny, Holt et al. 2009; O'Reilly and Hynynen 2010; Hsieh, Smith 
et al. 2011).  For example, Huang et al. (Huang, Xu et al. 2010) recently proposed to use phase-
change agents, such as perfluorocarbon-liquid emulsion droplets that vaporize upon heating, to 
detect the margins of ablation during high-intensity focused ultrasound.  Here, we propose an 
alternative strategy, in which Gd(III)-lipid microbubbles may serve as both a source and MRI 
beacon for acoustic cavitation.  Following the proposed mechanism given above, the MRI signal 
would increase from baseline tissue contrast to positive contrast, in a dose-dependent manner, as 
microbubbles are fragmented.  The change in signal intensity would provide a measure of the 
microbubble cavitation dose within the region of interest.  Thus, the Gd(III)-microbubbles 
developed here may serve as a theranostic agent to monitor treatment and minimize the side 










Chelation of the paramagnetic lanthanide Gd(III) to the DOTA ligand on the surface of lipid-
shelled microbubbles was achieved at a reaction temperature of 50 oC without degrading the 4-5 
µm microbubble size distribution.  The microbubbles were echogenic and provided contrast 
during high-frequency ultrasound imaging in vivo.  Surprisingly, MRI relaxometry showed that 
intact Gd(III)-bound microbubbles did not significantly enhance longitudinal or transverse 
proton relaxation.  However, the bilayer fragments of Gd(III)-bound microbubbles formed by 
cavitation resulted in a significant increase r1 and r2.  A mechanism based on bulk water access 
to the Gd(III) complex was proposed to explain the increase in MRI signal intensity observed 
upon conversion of the condensed monolayer form to the relaxed bilayer form.  Gd(III)-bound 












Chapter 4. Magnetic Resonance Properties of Gd(III)-Bound Lipid-Coated 
Microbubbles and their Cavitation Fragments 
4.1. Introduction 
Magnetic resonance imaging guided focused ultrasound surgery (MRIgFUS) is a rapidly 
developing medical technique that uses high intensity focused ultrasound to ablate tissue and 
magnetic resonance (MR) thermometry to monitor treatment (Cline, Schenck et al. 1992; Jolesz 
and Hynynen 2002; Jolesz and McDannold 2008).  Formation and transient cavitation of gas-
filled microbubbles nucleated from dissolved gases in tissue and blood plays an integral role in 
the efficacy of this therapy (Jolesz and McDannold 2008).  However, the nucleation of cavitation 
sites is unpredictable and can lead to deleterious effects outside the targeted region.  Thus, it is 
preferable to use preformed, stabilized microbubbles (1-10 µm diameter) that can interact with 
ultrasound waves in a more predictable manner (Jolesz and McDannold 2008).  Lipid-coated 
microbubbles are currently approved by the U.S. Food and Drug administration (FDA) for 
echocardiography and are currently being developed for expanded imaging capabilities (Lindner 
2004; Qin, Caskey et al. 2009) and therapeutic applications in drug, gene and gas delivery 
(Ferrara, Pollard et al. 2007; Coussios and Roy 2008; Swanson, Mohan et al. 2010; Sirsi, 
Hernandez et al. 2012).  One potential therapeutic application of microbubbles is the non-
invasive, localized and transient opening of the blood-brain-barrier (BBB) for targeted drug 
delivery to the brain.  Previously, lipid-coated microbubbles were shown to reduce the acoustic 
threshold needed for opening of the BBB in vivo (Choi, Feshitan et al. ; Hynynen, McDannold et 
al. 2001; Choi, Pernot et al. 2007; Xie, Boska et al. 2008; Marquet, Tung et al. 2011).  In 




payload (Ferrara, Pollard et al. 2007; Lentacker, De Smedt et al. 2009).  However, methods are 
unavailable to use MRI for tracking microbubbles and their interactions with ultrasound.  It 
therefore is desirable to develop MR-detectable microbubbles, so that MRI can be used to 
monitor and control not only thermal ablation, but also pharmaceutical delivery.   
In chapter 3, the MRI-contrast agent Gd(III)-DOTA was conjugated to the lipid shell of 
size-selected gas-filled microbubbles using a post-labeling technique.  Gd(III)-DOTA was 
conjugated to the primary amine on the headgroup of phosphatidylethanolamine (PE).  The effect 
of Gd(III)-bound microbubble cavitation on the MR signal (at 9.4 T) was determined by 
comparing r1 and r2* of 4-5 micron-sized gas core-containing Gd(III)-bound microbubbles to 
those of microbubbles that were fragmented by inertial cavitation into lipid fragments.  
Surprisingly, both r1 and r2* increased after the fragmentation of intact Gd(III)-bound 
microbubbles.  The explanation for this phenomenon was based on the difference in bulk water 
access to the lipid headgroup-labeled Gd(III)-complex for microbubbles versus the lipid 
fragments.  Paramagnetic Gd(III) ions reportedly enhance MR signal by interacting with nearby 
water protons (Toth, Helm et al. 2002).  Intact microbubbles, which comprise a highly condensed 
monolayer shell, may restrict access of aqueous protons to the Gd(III) bound lipid headgroup.  
Microbubble fragmentation converts the Gd(III) bound PE monolayer to a more relaxed 
liposomal bilayer structure, which may allow for greater access of water molecules to the 
Gd(III), increasing R1 and enabling higher signal intensities in T1-weighted images.   
One method of testing this hypothesis is to characterize the MR relaxation properties of 
intact and fragmented lipid microbubbles comprising a shell with Gd(III) preferentially 




brush on the lipid monolayer encapsulation.  Microbubble (or liposome) design requires the PEG 
brush to provide stability against coalescence (or fusion) and to protect against an immunogenic 
response in vivo (Allen 1994; Ferrara, Pollard et al. 2007).  Although, liposomes with Gd(III)-
labeled lipid headgroups have been designed for cellular and vascular imaging applications 
(Strijkers, Mulder et al. 2005; Ghaghada, Ravoori et al. 2009; Hak, Sanders et al. 2009), neither 
liposomes nor microbubbles with Gd(III) conjugated to the PEG brush have been documented.  
Comparison between the MR signal intensity induced by PEG-labeled Gd(III)-microbubbles and 
their liposomal fragments may shed some light into the exchange rate hypothesis that was 
originally proposed to explain the behavior of lipid headgroup-labeled Gd(III)-microbubbles 
under fragmentation.   
The microbubble gas core may also affect longitudinal and transverse relaxation.  
Previously, gas-filled microbubbles without Gd(III) reportedly enhanced R2* in a dose-dependent 
manner (Alexander, McCreery et al. 1996; Wong, Huang et al. 2004; Cheung, Chow et al. 2009).  
R2* is the additional enhancement of the transverse magnetization signal above of baseline R2 
that stems from inhomogeneities in the magnetic field.  The R2* enhancement produced by the 
microbubbles was attributed to the differences in magnetic susceptibility at the gas-liquid 
interface, which creates local inhomogeneities in the magnetic field that affect R2* decay.  The 
equation given below relates the approximate magnetic field perturbation caused by a single, 
isolated spherical gas-filled microbubble at a position described by cylindrical coordinates (r, θ) 
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where ∆B is the magnetic field perturbation, Bo is the static magnetic field vector, ∆χ represents 
the magnetic susceptibility difference between gas and liquid and R is the sphere radius.  Thus, 
the degree of magnetic field perturbation caused by the presence of a single gas bubble during 
MR analysis is theoretically dependent on gas volume and the susceptibility differences at the 
gas-liquid interface.  Alexander et al. (Alexander, McCreery et al. 1996) reported R2* 
enhancement from 9 different gas-types and the potential to use the gas-volume dependent 
susceptibility effect as a pressure sensor for evaluating cardiovascular function.  Cheung et al. 
(Cheung, Chow et al. 2009) reported an increase of R2* at 7 T in the rat brain as a function of 
microbubble volume fraction for both sulfur hexafluoride and air microbubbles.  Wong et al. 
(Wong, Huang et al. 2004) used the R2* enhancement induced by Optison (GE Healthcare) 
microbubbles for intravascular imaging of the rat liver with MRI.  Subsequent studies by Chow 
et al. (Chow, Chan et al.) and Yang et al. (Yang, Li et al. 2009) demonstrated additional 
enhancement of R2*  by loading  iron oxide into the shell of polymeric microbubbles (Chow, 
Chan et al. ; Yang, Li et al. 2009).  Finally, Liu et al. (Liu, Lammers et al. 2011)  reported an 
additional enhancement of both R1 and R2* after microbubble fragmentation with ultrasound.  
The additional MR enhancement after fragmentation was attributed to greater interaction of 
water protons with iron oxide in the shell fragments.  For lipid microbubbles loaded with 
paramagnetic Gd(III), it is desirable to determine the effects the paramagnetic ions and gas core 





In this report, the effects of microbubble gas core and Gd(III) conjugation on R1 and R2* were 
determined quantitatively by NMR.  The microbubble shell used in this study is lipid-based 
because of the advantages in biocompatibility and ultrasound compliance when compared to 
polymeric agents (Bloch, Wan et al. 2004).  A post-labeling protocol was used to generate lipid 
headgroup-labeled or PEG-labeled Gd(III)-microbubbles, and microbubbles without Gd(III) 
conjugated to the shell served as controls.  The changes in r1 and r2* of both lipid headgroup-
labeled and PEG-labeled Gd(III)-microbubbles after fragmentation were used to determine the 
potential mechanisms responsible for an increase in MR signal of fragmented lipid headgroup-
labeled Gd(III) microbubbles. 
 
4.2. Materials and Methods  
4.2.1.  Materials 
All solutions were prepared using filtered, 18 MΩ cm deionized water (Direct-Q, Millipore, 
Billerica, MA).  All glassware were cleaned with 70 vol% ethyl alcohol solution (Sigma-Aldrich; 
St. Louis, MO) and rinsed with deionized water.  The gas used to form microbubbles was 
perfluorobutane (PFB) at 99 wt% purity obtained from FluoroMed (Round Rock, TX).  1,2-
distearyol-sn-glycero-3-phosphoethanolamine (DSPE) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG(2000)-amine) were 
purchased from Avanti Polar Lipids (Alabaster, AL).  1,2-distearyol-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)5000] (DSPE-PEG(5000)) was obtained 
from NOF America Corporation (White Plains, NY).  1,4,7,10-Tetraazacyclododecane-1,4,7,10-




Macrocyclics (Dallas, TX) and dissolved in N,N-dimethylformamide (DMF; Sigma-Aldrich) 
prior to use.  Gadolinium (III) chloride (GdCL3) was purchased from Sigma Aldrich and 
dissolved in 0.2 M, pH 5.6 acetate buffer (VWR, Radnor, PA). 
 
4.2.2. Microbubble Generation and Size Isolation 
Microbubbles with primary amine lipid groups were formulated using a lipid suspension of 90% 
DSPE and 10% DSPE-PEG(5000) at 2 mg/mL in 100 mL PBS (pH 7.2, 0.15 M NaCL, 0.2 M 
phosphate).  Microbubbles with primary amine PEG groups were formulated using a lipid 
suspension of 90% DSPC and 10% DSPE-PEG(2000)-amine at 2 mg/mL in 100 mL PBS.  The 
lipid DSPC was selected to prevent headgroup conjugation.  Each solution was degassed by 
applying house vacuum with constant stirring.  The DSPE/DSPE-PEG(5000) solution was then 
preheated to 6 oC above the main phase transition temperature (Tm = 74 oC) of DSPE (Cevc and 
Marsh 1985).  Similarly, the DSPC/DSPE-PEG(2000)-amine solution was then preheated to 5 oC 
above the main phase transition temperature (Tm = 55 oC) of DSPC.   
The lipid mixture was sonicated with a 20-kHz probe (model 250A, Branson Ultrasonics; 
Danbury, CT) at low power (3 W) to disperse the lipid aggregates into small, unilamellar 
liposomes.  PFB gas was introduced by flowing it over the surface of the lipid suspension.  
Higher power sonication (33 W) was applied to the suspension for about 10 seconds at the gas-
liquid interface to generate microbubbles.  Size distribution of the microbubbles was determined 
by laser light obscuration and scattering (Accusizer 780A, NICOMP Particle Sizing Systems, 




diluted into a flask containing 30 mL of distilled water under gentle mixing.  All samples were 
measured in triplicate and analyzed for both number- and volume-weighted size distributions.  
The size-selected microbubbles used in this study were 1-2 µm in size since this size range 
provided lower buoyancy and, consequently, improved measurement consistency during NMR 
data collection as compared to the 4-5 µm bubbles.  The 1-2 µm microbubble size distribution 
was refined using methods described in chapter 2. 
 
4.2.3.  Synthesis of Headgroup-labeled (Gd(III)-PE) and PEG-labeled (Gd(III)-PEG-PE) 
Microbubbles 
Gd(III)-bound microbubbles shells were fabricated using the post-labeling technique (Figure 4.1) 
described in chapter 3.  To summarize briefly, during headgroup labeled Gd(III)-microbubble 
(Gd(III)-PE) formulation, the macrocyclic ligand DOTA was conjugated via an NHS reaction at 
room temperature to the primary amine located on the headgroup of DSPE.  Excess DOTA-NHS 
ions were removed by several cycles of washing/centrifugation (5 minute, 300 RCF) using pH 
5.6 Acetate buffer.  The lanthanide Gd(III) was chelated to the DOTA group bound to the lipid 
headgroup.  The chelation reaction was carried out at 50 oC for 2 hours.  Excess Gd(III) ions 
were removed by several cycles of washing/centrifugation (5 minute, 300 RCF) using pH 5.6 





Figure 4.1: Schematic of Gd(III)-DOTA conjugation to microbubble shell. A) Gd(III)-PE. 
B) Gd(III)-PEG-PE.  
Similarly, PEG-labeled Gd(III) microbubbles (Gd(III)-PEG-PE) were fabricated using the same 
post-labeling technique.  DOTA was conjugated to the primary amine group located on the distal 
end of DSPE-PEG(2000) amine.  Excess DOTA-NHS ions were removed by several cycles of 
washing/centrifugation (5 minute, 300 RCF) using pH 5.6 Acetate buffer.  The lanthanide 
Gd(III) was chelated to the DOTA group bound to the PEG-PE group.  The chelation reaction 
was carried out at 45 oC for 2 hours.  Excess Gd(III) ions were removed by several cycles of 
washing/centrifugation (5 minute, 300 RCF) using pH 5.6 Acetate buffer followed by several 





4.2.4.  Characterization of Gd(III)-bound Microbubbles and Cavitation Fragments 
Microbubble size distribution and concentration after chelation reaction were determined by 
using the Accusizer.  The concentration of Gd(III) bound to the microbubble shell was 
determined by inductively coupled mass spectroscopy (ICP-MS, Agilent technologies, Santa 
Clara, CA).  Destruction/fragmentation of Gd(III)-PE and Gd(III)-PEG-PE microbubble 
suspensions was accomplished by simultaneous bath sonication and heating to 80 oC and 60 oC 
for 10 mins respectively.  A Malvern ZetaSizer (Worcestershire, United Kingdom) was used to 
determine the size of liposomal fragments.   
 
4.2.5.  NMR Characterization of Intact and Fragmented Gd(III)-bound Microbubbles 
The effect of the Gd(III)-bound microbubbles on the T1 and T2* relaxation times was determined 
using NMR.  Intact Gd(III)-PE or Gd(III)-PEG-PE  microbubbles suspension at a concentration 
of at least 3 x 1010 mL-1 were mixed with saline in four different volume ratios (25, 50, 75 and 
100 %) in a 2 mm outer diameter NMR compatible capillary tube (Wilmad-LabGlass, Vineland, 
NJ), which was flame-sealed.  The average starting Gd(III) concentration of Gd(III)-PE and 
Gd(III)-PEG-PE samples was 0.45 mM and 0.1 mM respectively.  Intact and fragmented 1-2 µm 
microbubbles without Gd(III) binding were used as controls.  End-over-end mixing, performed 
five times before each measurement, homogenized the microbubble suspensions and further 
mitigated the effects of bubbles rising due to their buoyancy.  A 1.5 T vertical NMR 
spectroscopy system was used to measure T1 and T2* relaxation times.  T1 relaxation times were 




ms up to 30 s.  T2* relaxation times were determined using a Carr-Purcell-Meiboom-Gill 
(CPMG) sequence with a 4 ms intercho time, and a repetition time of at least 5 T1 for each 
sample.  The T1 and T2* times induced by the intact microbubbles were measured first.  Next, the 
sealed capillary containing the intact microbubbles was heated and sonicated to produce a 
solution of Gd(III)-bound lipid fragments.  Fragmentation of Gd(III)-PE and Gd(III)-PEG-PE 
microbubbles were accomplished by heating to 80 oC and 60 oC for 10 minutes respectively.  
Finally, the T1 and T2* times induced by the fragmented microbubbles were determined.  All T1 
and T2* measurements were repeated in triplicate.  Molar relaxivities (r1 and r2*) were calculated 
from slopes of regression lines of the plot of R1 and R2* versus Gd(III) concentration.  A two-
tailed unpaired student t-test was used to determine the significance between r1 and r2* of 
fragmented versus intact samples assuming a Gaussian distribution. 
 
4.3. Results and Discussions  
4.3.1.  Preparation of Gd(III)-bound Microbubbles 
4.3.1.1. Headgroup-labeled Microbubbles (Gd(III)-PE) 
The size isolation technique produced 1-2 µm diameter microbubbles at a concentration of a 
least 1 x 1011 mL-1.  Figure 4.2a shows the size distribution of microbubbles before and after 
DOTA conjugation to the amine-containing lipid (DSPE) on the monolayer via an NHS-coupling 
reaction at room temperature.  The average microbubble concentration decreased by 
approximately 41 % after DOTA conjugation.  Figure 4.2b shows the size distribution of 
microbubbles before and after Gd(III) chelation to DOTA bound to the DSPE monolayer at 50 




reaction.  The mean and median number diameter of microbubbles changed by less than 1% 
before and after DOTA conjugation and Gd(III) chelation.  This indicated that the post-labeling 
strategy to available PE groups reduced microbubble concentration but minimally affected 1-2 
micron size monodispersity.  The average Gd(III) ions per Gd(III)-PE microbubble determined 
by ICP-MS was 7.3 x 106 ± 2.3 x 106 ions/microbubble (1.3 x 106 ± 4.1 x 105 ions/µm2).  
Assuming spherical microbubbles with an average molecular area of 0.4 nm2, there was on 
average ~64 % of Gd(III)-DOTA binding to available PE groups.  Dynamic light scattering 
measurements indicated that fragmentation of the Gd(III)-PE microbubbles by heating and bath 







Figure 4.2. A) Number-weighted size distributions of DSPE microbubbles before and after 
conjugation with DOTA-NHS.  B) Number-weighted size distributions of lipid-bound 
DOTA-microbubbles before and after Gd(III) chelation at 50 oC.  
 
4.3.1.2. PEG-labeled Microbubbles (Gd(III)-PEG-PE) 
As before, the size isolation technique produced 1-2 µm diameter microbubbles at a 
concentration of at least 1 x 1011 mL-1.  Figure 4.3a shows the size distribution of microbubbles 
before and after DOTA conjugation to the distal end of the amine-containing PEG-PE on the 
monolayer via an NHS-coupling reaction at room temperature.  The average concentration of 1-2 




shows the size distribution of microbubbles before and after Gd(III) chelation to the DOTA-
bound PEG-PE on the monolayer at 50 oC.  The average microbubble concentration decreased by 
41 % after the 2-hour chelation.  The mean and median number diameter of microbubbles 
changed by less than 1 % before and after DOTA conjugation and Gd(III) chelation.  This 
indicated that the post-labeling strategy to available PEG-PE groups reduced microbubble 
concentration but minimally affected 1-2 micron size monodispersity.  The average Gd(III) ions 
per Gd(III)-PEG-PE microbubble determined by ICP-MS was 6.3 x 105 ± 2.1 x 105 
ions/microbubble (1.4 x 105 ± 6.7 x 104 ions/µm2).  Again, assuming spherical microbubbles 
with an average molecular area of 0.4 nm2, there was on average ~53 % of Gd(III) binding to 
available reactive PEG-PE groups.  Dynamic light scattering measurements indicated that 
fragmentation of Gd(III)-PEG-PE microbubbles by heating and bath sonication resulted in 
bimodal lipid fragments of 84 ± 18 nm and 340 ± 61 nm in diameter.  This bimodality suggests 
that Gd(III)-PEG-PE microbubbles formed a mixture of lipid vesicles such as micelles and 





Figure 4.3. A) Number-weighted size distributions of DSPE/DSPE-PEG 2000 amine 
microbubbles before and after conjugation with DOTA-NHS.   B) Number-weighted size 
distributions of PEG-bound DOTA-microbubbles before and after Gd(III) chelation at 45 
oC. 
  
4.3.2. NMR Characterization of Intact and Fragmented Gd(III)-Bound Microbubbles  
4.3.2.1. Control Microbubbles (No Gd(III)) 
Figure 4.4a and 4.4b show plots of the longitudinal (R1 = 1/T1) and transverse (R2* = 1/T2*) 




9.8 to 2.1 ± 0.31 s-1 volume-fraction-1 during microbubble fragmentation.  There was no 
appreciable change in r1. 
 
Figure 4.4: Relaxation rate of control microbubbles (No Gd(III)) versus gas volume 
fraction. A) Longitudinal relaxation rate (R1). B) Transverse relaxation rate (R2*).  
 
4.3.2.2. Relaxation Rate of Intact and Fragmented  Gd(III)-PE Microbubbles 
Figure 4.5 shows representative plots of R1 and R2* versus Gd(III) concentration for Gd(III)-PE 
microbubbles.  R1 and R2* increased in a dose-dependent manner for both the intact and 




and fragmented Gd(III)-PE microbubbles for 3 independent experiments.  On average the value 
of r1 increased by a factor of 2.4 after microbubble fragmentation (p < 0.05).  However, r2* 
remained relatively unchanged after microbubble fragmentation (p = 0.9).  Therefore, 
fragmentation of Gd(III)-PE microbubbles enhanced R1, but only slightly changed R2*. 
 
 
Figure 4.5: Relaxation rates of intact and fragmented Gd(III)-PE microbubbles versus 
Gd(III) concentration. A) Longitudinal relaxation rate (R1). B) Transverse relaxation rate 
























Trial 1 8.6 x 106 6.6 ± 0.19 16 ± 0.39 23 ± 1.4 22 ± 2.5 
Trial 2 8.7 x 106 8.8 ± 0.36 26 ± 0.55 37 ± 0.40 37 ± 0.33 
Trial 3 4.7 x 106 7.3 ± 8.1 14 ± 13 43 ± 4.4 41 ± 1.6 
Similar to the T1-weighted MRI analysis of 4-5 micron sized Gd(III)-PE microbubbles in 
chapter 3, fragmentation of the 1-2 micron sized Gd(III)-PE microbubbles resulted in an increase 
in r1.  From the control microbubble experiments, it was evident that there is virtually no 
contribution to T1 relaxation from either the lipid bilayer or the perfluorobutane gas core.  These 
results support the hypothesis in chapter 3 of an enhanced exchange rate of protons with Gd(III) 
in the relaxed bilayer versus the condensed monolayer.  
We suggest that the enhancement in proton exchange occurred as the lipid headgroup 
area increased with the transformation from a monolayer to bilayer configuration (figure 4.6A).  
Israelachvili provided a simple relation for the optimal headgroup area (ao) in terms of a balance 





      (4.2) 
where K is a constant accounting for steric repulsion in the interfacial region and γ is the 
interfacial tension.  Based on this simple approximation, the equilibrium headgroup area is 
expected to increase ~70% upon going from a gas-water interface (γmonolayer ~ 73 mN/m) to a 




an increase in headgroup area may allow more water molecules to permeate into the headgroup 
region and interact with the chelated Gd(III) ions.     
 
Figure 4.6. Schematic demonstrating hypothetical mechanisms governing changes in a) r1 
of Gd(III)-PE microbubbles and b)  r2* of Gd(III)-PEG-PE microbubbles.  
 The trend in T2* is different (Figure 4.5B, table 4.1) than T1, as r2* of the intact and fragmented 
Gd(III)-PE microbubbles were similar in magnitude, especially for the first two trials.  From 
observation of the control microbubbles without Gd(III), it is apparent that the intact 
microbubbles provide a ~35-fold greater increase of R2* than the lipid fragments. This result 
indicates that the gas core of the Gd(III)-PE microbubbles induces an independent enhancement 




filled microbubbles (without Gd(III))(Chow, Chan et al. ; Alexander, McCreery et al. 1996; 
Wong, Huang et al. 2004; Cheung, Chow et al. 2009; Yang, Li et al. 2009; Liu, Lammers et al. 
2011).  Our results demonstrate that this gas susceptibility behavior affects R2*, but not R1.  R1 is 
only sensitive to relaxation processes at the proton Larmor frequency (64 MHz at 1.5 T) 
(Abragam 1961; Slichter 1990; Levitt 2008), while the R2* signal is sensitive to inhomogeneities 
in the magnetic field such as those present at gas-liquid interfaces.  Therefore, we propose that 
the increase in R2* due to intact Gd(III)-PE microbubbles stems from a combination of a weak 
augmentation induced by Gd(III) in the highly-packed lipid monolayer and a susceptibility 
enhancement from the gas core.  After microbubble fragmentation, the gas-susceptibility 
enhancement dissipates, but the remnant lipid fragments (containing no gas) still enhance R2* by 
virtue of enhanced proton exchange with Gd(III) in the relaxed lipid bilayer.  Observation of the 
sample from trial 3, further supports this explanation, as a slightly higher gas-fraction to Gd(III) 
ratio, ultimately resulted in intact Gd(III)-PE microbubbles with a slightly larger r2* value than 
the lipid fragments.  It may be worthwhile to explore the effects of changing the gas composition 
of the Gd(III)-PE microbubbles on r2*.  The magnetic susceptibility constant of gases varies 
depending on whether the gas is diamagnetic or paramagnetic, and although the magnetic 
susceptibility of PFB gas has not been reported, the values for diamagnetic gases like Nitrogen 







4.3.2.3. Relaxation Rate of Intact and Fragmented  Gd(III)-PEG-PE Microbubbles 
Figure 4.7 shows representative plots of R1 and R2* versus Gd(III) concentration for Gd(III)-
PEG-PE microbubbles.  Again, R1 and R2* increased in a dose-dependent manner for both the 
intact and fragmented microbubbles.  However, the trendlines changed significantly upon 
fragmentation in comparison to Gd(III)-PE microbubbles.  Table 4.2 summarizes the calculated 
values of r1 and r2* of the intact and fragmented Gd(III)-PEG-PE microbubbles for 3 independent 
experiments.  The calculated r1 values of the Gd(III)-PEG-PE microbubbles decreased on 
average by a factor of 2.1 after microbubble fragmentation (p = 0.26).  Similarly, r2* decreased 
on average by a factor of 8 after fragmentation (p < 0.05).  Moreover, the decrease in magnitude 
of r2* was about 2 times greater than that of r1.  Evidently, fragmentation of Gd(III)-PEG-PE 






Figure 4.7: Relaxation rates of intact and fragmented Gd(III)-PEG-PE microbubbles 
versus Gd(III) concentration.  A) Longitudinal relaxation rate (R1). B) Transverse 
relaxation rate (R2*). Figure shown is a representative data set. 
 
















Trial 1 5.0 x 105 18 ± 0.030 14 ± 0.10 190 ± 1.3 36 ± 1.2 
Trial 2 8.7 x 105 14 ± 0.33 4.6 ± 1.3 98 ± 2.9 11 ± 2.9 




We sought to further explore the proton exchange rate mechanism, proposed earlier as the 
reason for the increase in r1 for Gd(III)-PE microbubbles, by characterizing the MR signal 
induced from a construct consisting of Gd(III) bound to the PEG brush of the lipid microbubble.  
PEG is a highly flexible and dynamic molecule under these conditions (Kuhl, Leckband et al. 
1994; Kuhl, Majewski et al. 1999; Moore and Kuhl 2006), and therefore the relaxation rate of 
terminal Gd(III) groups is expected to be relatively insensitive to changes in packing of the 
underlying lipids.  Contrary to Gd(III)-PE microbubble behavior, both the r1 and r2* relaxivity of 
the Gd(III)-PEG-PE microbubbles dropped in magnitude after microbubble fragmentation.  
The decrease in r1 suggests that the underlying mechanism governing changes in r1 after 
fragmentation of the Gd(III)-PEG-PE microbubbles is different from that governing the changes 
in r1 of Gd(III)-PE microbubbles. With Gd(III) bound to the PEG, the proton exchange 
mechanism proposed to govern changes in relaxivity of the Gd(III)-PE microbubbles would be 
expected to play a minimal role in the Gd(III)-PEG-PE microbubbles since the effective PEG 
molecular area and water access to Gd(III) would remain the same after microbubble 
fragmentation.  One possible explanation for the decrease in r1 of Gd(III)-PEG-PE microbubbles 
is that differences in rotational correlation times between the intact and fragmented complexes 
dominates r1 behavior.  Relaxation theory predicts that optimization of one or more parameters 
governing the inner sphere relaxivity of Gd(III) such as hydration number, electronic relaxation, 
proton exchange rate and rotational correlation time, makes the other parameters more limitative 
(Toth, Helm et al. 2002).  Thus, assuming that the proton exchange mechanism and all other 
relaxation parameters remains unchanged, then the differences in rotational correlation times or 
between the microbubbles and lipid fragments could dictate the differences in relaxivity from 




possibly tumbles at a slower rate, leading to larger r1 as compared to the smaller-sized lipid 
fragments that tumble at a faster rate.  However, further experimentation will be needed to 
validate this hypothesis.  
The changes in r2* can be attributed primarily to the strong effect the gas creates on the 
transverse magnetization signal.  As explained above for the Gd(III)-PE microbubbles, the gas 
core of the intact Gd(III)-PEG-PE microbubble induces an independent enhancement of R2*.  
This is supported by the observation that fragmentation of the Gd(III)-PEG-PE microbubbles 
correlated with a significant decrease of R2*.  However, unlike the Gd(III)-PE sample, the signal 
loss from microbubble fragmentation was not compensated by the presence of the remnant 
Gd(III)-PEG-PE lipid fragments.  Overall, the lowering of r1 and r2* values from fragmenting 
Gd(III)-PEG-PE microbubbles seems to support the hypothesis proposed for the changes in r1 in 
the Gd(III)-PE microbubbles.  Ultimately, it appears the effect of Gd(III)-bound microbubble 
cavitation on the MR signal depends on the placement of the Gd(III) (lipid labeled versus PEG 
labeled) on the shell and the presence of the gas core (for T2*).  For example, one may monitor 
FUS treatment by monitoring cavitation of lipid headgroup-labeled Gd(III)-microbubbles via 
changes in T1, or via changes in T2* in the case of PEG-labeled Gd(III)-microbubbles.   
 
4.4. Conclusions 
The paramagnetic MRI contrast agent, Gd(III)-DOTA, was conjugated to two different 
groups on the lipid monolayer shell of the microbubble: the PE lipid headgroup region or the 




specifically enhanced R2* in a dose-dependent manner, but not R1.  The increase in r1 after 
fragmentation of Gd(III)-PE microbubbles suggested that the corresponding expansion of the 
lipid headgroup area increased proton exchange with the Gd(III)-bound lipid headgroup and 
enhanced R1.  However, the decrease in r1 from fragmenting Gd(III)-PEG-PE microbubbles 
indicated that a different relaxation mechanism was at play, which was minimally affected by 
changes in lipid headgroup area.  Therefore, the effect of Gd(III)-bound microbubble cavitation 
on the NMR signal depends on the location of Gd(III) on the lipid shell (PEG-labeled or lipid 
headgroup-labeled) and the presence of the gas core.  These results show how NMR may be used 
to provide information on lipid headgroup packing, and they may hold implications for detecting 




Chapter 5. Opening the Blood-Brain Barrier with Gd(III)-bound Lipid-
stabilized Microbubbles  
5.1. Introduction 
One main bottleneck for the treatment of diseases found in the central nervous system is 
lack of effective delivery of larger drug compounds to the brain.  This restriction is primarily 
imposed by action of the brain’s semi-permeable microvasculature known as the blood-brain 
barrier (BBB).  The BBB generally excludes compounds greater than 400 Da, and thereby 
prevents neuropharmaceutical agents, such as inhibitors and antibodies, from reaching their 
desired target (Pardridge 2005).  Focused ultrasound (FUS) with an intravenous injection of 
lipid-stabilized, gas-filled microbubbles has been demonstrated to induce the transient non-
invasive and localized opening of the BBB (Hynynen, McDannold et al. 2005; Choi, Pernot et al. 
2007).  Subsequent studies have demonstrated a dependence of the acoustic pressure threshold 
needed to induce BBB opening on the size range of the microbubbles (Choi, Feshitan et al. 2010; 
Tung, Vlachos et al. 2011; Vlachos, Tung et al. 2011).  Microbubbles of size class 4-5 and 6-8 
micron in diameter induced BBB opening at a peak rarefactional driving pressure of 0.45 MPa, 
while 1-2 micron sized microbubbles required a driving pressure of 0.6 MPa.  Additional studies 
demonstrated the feasibility to open the BBB in non-human primates (Marquet, Tung et al. 
2011). 
For these applications, it would be advantageous to use a microbubble formulation 
detectable by magnetic resonance imaging (MRI), which could be used to measure microbubble 
concentration, image cavitation events and determine the biodistribution of microbubble shell 




monitor FUS treatment, similar to how changes in temperature are used to monitor treatment in 
real-time during MRI-guided FUS therapy applications (Cline, Schenck et al. 1992; Cline, 
Hynynen et al. 1995; Hynynen, Freund et al. 1996).  Alternatively, MRI-detectable microbubbles 
could be used to track the deposition profile of microbubble shell material (a potential surrogate 
for an attached drug) by scanning the sonicated region after FUS treatment.   
In chapter 3 of this thesis, an MRI-detectable microbubble formulation was developed 
method by labeling the MRI-contrast agent Gd(III)-DOTA to the lipid shell of size-selected gas-
filled microbubbles.  Gd(III)-DOTA was conjugated to the primary amine on the headgroup of 
phosphatidylethanolamine (PE).  The effect of Gd(III)-bound microbubble cavitation on the MR 
signal (at 9.4 T) was determined in vitro by comparing both longitudinal (r1) and transverse (r2) 
relaxivity of 4-5 micron-sized gas core-containing Gd(III)-bound microbubbles to those of 
microbubbles that were fragmented into lipid shell fragments.  Analysis revealed that both r1 and 
r2 increased after the fragmentation of intact Gd(III)-bound microbubbles.  Additionally, the 
Gd(III)-bound microbubbles were also found to be echogenic in vivo during high-frequency 
ultrasound imaging of the mouse kidney. The echogenicity indicated that conjugation of the MRI 
contrast agent to the microbubble lipid shell did not affect its behavior as an ultrasound contrast 
agent.   
In another study, Liao et al (Liao, Liu et al. 2012) developed albumin microbubbles 
containing a shell surface-conjugated with Gd(III)-DTPA to serve as dual mode contrast agents 
for ultrasound and MR imaging. FUS in combination with these Gd(III)-labeled albumin 
microbubbles were used to disrupt the BBB and induce intracerebral hemorrhaging at a pressure 




hemorrhaging was demonstrated using MRI in combination with the Gd(III)-labeled 
microbubbles.  However, it is desirable to open the BBB at a safer pressure threshold of 0.45 
MPa using the Gd(III)-labeled microbubbles, and then image the sonicated region of the brain 
with MRI for the presence of Gd(III)-labeled lipid vesicles.  Furthermore, lipid-stabilized 
microbubbles are preferred for this purpose due to their higher ultrasound compliance in 
comparison to the albumin-shelled counterparts (Sirsi and Borden 2009). 
In this chapter, we detail the opening of the BBB using FUS at 1.5 MHz and 0.4 MPa and 
4-5 micron lipid-stabilized microbubbles labeled with Gd(III)-DOTA, and the feasibility to use 
MRI to image the sonicated region for presence of Gd(III)-labeled lipid vesicles after FUS 
treatment. The microbubbles in this study were surface-conjugated with Gd(III)-DOTA since the 
ligand DOTA is known to provide a stronger chemical bond with Gd(III) than DTPA, which 
reduces the potential for the release of free toxic Gd(III) ions (Sherry, Caravan et al. 2009). 
 
5.2. Materials and methods 
Sonication Protocol 
All animal procedures were approved by the Columbia University Institutional Animal Care and 
Use Committee. The sonication protocol was adapted from the previously reported techniques 
(Choi, Pernot et al. 2007; Choi, Feshitan et al. 2010; Vlachos, Tung et al. 2011).  A FUS 
transducer (frequency: 1.5 MHz) was confocally aligned with a pulse-echodiagnostic transducer 
(frequency: 7.5 MHz). A water-filled cone was mounted onto the transducer and attached to a 




matching circuit and driven by a function generator (Agilent, Palo Alto, CA) and a 50-dB power 
amplifier (ENI Inc., Rochester, NY). The diagnostic transducer was driven by a pulser-receiver 
system (Panametrics, Waltham, MA) connected to a digitizer (Gage Applied Technologies, Inc., 
Lachine, QC, CAN). Pressure measurements of the FUS transducer were made with a needle 
hydrophone in a water tank.  Each mouse (n = 2, Strain C57BL/6 sex: male) was anesthetized 
with isoflurane, placed prone, and immobilized by a stereotaxic apparatus. The mouse hair was 
removed, ultrasound-coupling gel was applied on the skin, and a water-filled container sealed at 
the bottom was placed on the head.  The transducers were submerged in the water and their foci 
were positioned to overlap with the right hippocampus of the brain.  The left hippocampus was 
not targeted and was used as the control.  The 4-5 micron lipid-stabilized microbubbles labeled 
with Gd(III)-DOTA were fabricated using the post-labeling technique previously described in 
chapter 3 and injected intravenously (IV) through the tail vein at a concentration of 107 mL-1 
using a 30 G needle.  The right hippocampal region of the brain was sonicated 1 min after the 
microbubble injection using pulsed FUS (burst rate: 10 Hz; burst cycles: 100; duty cycle: 
0.067%; frequency: 1.5 MHz) at a peak-rarefactional pressure of 0.45 MPa for a duration of 60 s.  
Previous studies (Choi, Feshitan et al. 2010; Tung, Vlachos et al. 2011) have shown that the safe 
acoustic pressure for microbubble-mediated BBB opening lies between 0.30 and 0.45 MPa. 
 
MRI protocol 
 All the mice were imaged in a vertical bore 9.4 T MRI system (DRX400, Bruker Biospin, 
Billerica, MA) following previously developed protocols (Choi, Feshitan et al. 2010; Tung, 




the mouse during the MRI procedure.  A two-dimensional FLASH T1-weighted sequence 
(TR/TE  = 230/3.3 ms; flip angle: 70o; NEX = 18; scan time: 9 min 56 s, matrix size: 256 x 192; 
spatial resolution: 86 x 86 µm2; slice thickness: 500 µm with no interslice gap) was utilized to 
image the sonicated hippocampus (Vlachos, Tung et al. 2010; Vlachos, Tung et al. 2011).  The 
scanning sequence was initially applied ~30 minutes after sonication of the right hippocampus in 
the presence of the Gd(III)-bound microbubbles.  The presence of Gd(III) on the lipid shell of 
microbubbles was qualitatively confirmed by MR imaging of a centrifuge tube containing a 100 
µL aliquot of Gd(III) microbubble that were fragmented into constitutive lipid fragments using a 
combination of ultrasound and heating (data not shown).  A second scan was applied ~50 
minutes (~90 mins after sonication) after intraperitoneal injection of 0.30 ml BBB-impermeable, 
MRI contrast agent, Omniscan (GE Healthcare, Princeton, NJ), which allowed for sufficient time 
for Omniscan to diffuse into the sonicated hippocampus (Choi, Pernot et al. 2007; Choi, Feshitan 
et al. 2010).  Omniscan (Gd(III)-DTPA-based) is used to confirm BBB opening because it 
reduces the longitudinal relaxation time (T1) when released in the extravascular extracellular 
space, thus augmenting the local T1-weighted contrast.   
 
5.3. Results 
Figure 5.1B shows the image of the mouse brain after sonication of the right hippocampus in the 
presence of the Gd(III)-labeled microbubbles.  As is evident from the image, there was no 
observable increase in T1-weighted contrast in the right (sonicated) hippocampus after FUS 
sonication in presence of the Gd(III)-labeled microbubbles.  Figure 5.1C shows the image of the 




microbubbles followed by intraperitoneal injection of Omniscan.  As is evident from the image, 
there was a significant increase in T1-contrast in the sonicated region, which provided 
confirmation that the BBB was opened.  There was no observable increase in contrast in the 
control hippocampus in all cases. 
 
Figure 5.1. MRI images of the mouse brain: a) Unperturbed. b) ~40 mins after sonication 
of the right hippocampus in the presence of Gd(III)-labeled microbubbles. c) At least 100 
mins after sonication in the presence of Gd(III)-labeled microbubbles and ~60 mins after 
injection of Omniscan. 
  
5.4. Discussion  
FUS in combination with 4-5 micron sized Gd(III)-DOTA-labeled microbubbles was used to 
open the BBB in the right hippocampus of the mouse brain at a pressure threshold of 0.45 MPa.  




region after the injection of Omniscan. This enhancement is attributed to stem from combination 
of the intraperitoneal administration of Omniscan and time difference (50 mins) between its 
injection and the MRI scan.  The intraperitoneal injection method is known to allow for the slow 
uptake and diffusion of the contrast media to the sonicated area, which improves the probability 
that it is still present at the region of interest during MRI scanning (Choi, Pernot et al. 2007).   
This result indicated that the conjugation of the MRI contrast agent to the lipid shell minimally 
affected its capability to open the BBB at the safe pressure threshold used in previous studies 
(Choi, Feshitan et al. 2010; Tung, Vlachos et al. 2011; Vlachos, Tung et al. 2011).  
MRI was used to image the sonicated region for the presence of Gd(III)-labeled vesicles and 
to confirm BBB opening.  In chapter 3 and 4 of this thesis, the fragmentation of the lipid 
headgroup labeled Gd(III) microbubbles into constitutive lipid vesicles resulted in an increase in 
longitudinal relaxivity (r1) in vitro. As a result, the presence of Gd(III)-bound lipid shell 
fragments at the sonicated hippocampus was expected to produce an increase in the local T1-
weighted MRI contrast; however, there was no observable increase in T1 signal.  One hypothesis 
for the lack of T1-contrast enhancement in vivo may be due to lengthy time difference (~30 mins) 
between sonication in the presence of the intravenously administered Gd(III)-labeled 
microbubbles and commencement of MRI scanning.  This time difference possibly resulted in 
clearance of the Gd(III)-labeled vesicles from the sonicated regions by various mechanisms such 
as blood flow.  Alternatively, the concentration of the Gd(III) lipid shell that may have been 
present at the scanning region may not have been high enough to produce a noticeable increase 
in T1-contrast above the baseline level.   
One potential method to improve the chances of imaging the presence of Gd(III)-labeled 




imaging using real-time MRI guidance similar to that adapted in MRI-guided FUS therapy 
devices (Cline, Schenck et al. 1992; Cline, Hynynen et al. 1995; Hynynen, Freund et al. 1996; 
Jolesz and McDannold 2008).  Alternatively, the Gd(III)-labeled microbubble shell may be 
designed to incorporate a targeting peptide that can specifically bind to the BBB receptor and 
reduce the possibility of clearance from the region of interest.  These and other considerations 
may potentially improve the ability to track the fate of the Gd(III)-labeled microbubbles after 
FUS treatment in vivo. 
 
5.5. Conclusion 
FUS in combination with intravenously injected 4-5 micron lipid-stabilized microbubbles labeled 
with Gd(III)-DOTA successfully induced BBB opening at a safe pressure threshold.  The 
increase in T1-weighted MRI contrast after injection of Omniscan was used to confirm BBB 
opening at the sonicated region.  The threshold corresponded to that used to open the BBB using 
4-5 micron and 6-8 micron sized microbubbles without Gd(III)-DOTA.  However, there was no 
observable increase in T1-weighted contrast in the sonicated region after FUS application in the 
presence of the Gd(III)-labeled microbubbles.  In the future, a potential strategy to increase 
likelihood of imaging the Gd(III)-labeled shell after FUS sonication may require minimizing the 






Chapter 6: Concluding Remarks and Future Directions 
6.1. Accomplishment of Specific Aims 
6.1.1 Microbubble Size Isolation by differential centrifugation   
This study detailed a methodology to generate lipid-coated, perfluorobutane-filled 
microbubbles and isolate their size fractions based on migration in a centrifugal field. 
Polydispersity of the freshly sonicated suspension was characterized by particle sizing and 
counting through light obscuration/scattering and electrical impedance sensing, fluorescence and 
bright-field microscopy and flow cytometry. We found that the initial microbubble size 
distribution was polydisperse. Smaller microbubbles were more abundant. Differential 
centrifugation was used to isolate the 1–2 and 4–5 µm diameter fractions.  Isolated microbubbles 
were demonstrated to be stable over two days. After two weeks, however, more dilute 
suspensions (<1 vol%) were susceptible to Ostwald ripening. For example, 4–5 µm 
microbubbles disintegrated into 1–2 µm microbubbles. This latter observation indicated the 
existence of an optimally stable diameter in the 1–2 µm range for these lipid-coated 
microbubbles. Overall, differential centrifugation provided a rapid and robust means for size 
selection and reduced polydispersity of lipid-coated microbubbles. 
 
6.1.2. Theranostic Gd(III)-Lipid Microbubbles for MRI-guided Focused Ultrasound 
Surgery  
This study described a technique to synthesize a biomaterial consisting of Gd(III) ions 
chelated to lipid-coated, size-selected microbubbles for utility in both magnetic resonance and 
ultrasound imaging. The macrocyclic ligand DOTA-NHS was bound to 




Gd(III) was then chelated to DOTA on the microbubble shell. The reaction temperature of 50 oC 
was optimized to increase the rate of Gd(III) chelation while maintaining microbubble stability. 
The Gd(III)-bound microbubbles were found to be echogenic in vivo during high-frequency 
ultrasound imaging of the mouse kidney. The Gd(III)-bound microbubbles also were 
characterized by magnetic resonance imaging (MRI) at 9.4 T by a spin-echo technique.  This 
initial analysis with MRI revealed that Gd(III) relaxivity increased significantly, and in a 
concentration-dependent manner, after microbubble fragmentation into non-gas-containing lipid 
bilayer remnants. We attributed this behavior to an increase in water proton exchange with the 
Gd(III)-labeled lipid fragments caused by an increase in the lipid headgroup area that 
accompanied the lipid shell monolayer to bilayer transition.   
 
6.1.3.  Magnetic Resonance Properties of Gd(III)-Bound Lipid-Coated Microbubbles and 
their Cavitation Fragments 
In this study, we sought to explore the mechanism governing the changes in r1 and r2* 
after fragmentation of microbubbles consisting of Gd(III) labeled to two different groups on the 
lipid monolayer shell: the phosphatidylethanolamine (PE) lipid headgroup region or the distal 
region of the polyethylene-glycol (PEG) brush.  Nuclear magnetic resonance (NMR) analysis at 
1.5 T of the lipid headgroup labeled Gd(III)-microbubbles revealed that r1 increased on average 
by a factor of 2.4 after microbubble fragmentation, while r2* was unchanged.  Analysis of PEG-
labeled Gd(III)-microbubbles revealed that r1 and r2* decreased on average by a factor of 2.1 and 
8 respectively, after microbubble fragmentation.  Further analysis revealed that the microbubble 
gas core enhanced the transverse MR signal (T2*) in a dose-dependent manner but minimally 




Gd(III)-microbubble cavitation on the MR signal is dependent on the location of Gd(III) on the 
lipid shell (lipid headgroup-labeled or PEG-labeled) and the presence of the gas. 
 
6.1.4. Opening the Blood-brain Barrier with Gd(III)-bound Lipid-stabilized Microbubbles 
The aim of this study was to demonstrate the feasibility to safely and non-invasively open the 
BBB with Gd(III)-DOTA-labeled lipid-stabilized microbubbles and to determine the potential of 
imaging the sonicated region for the presence of lipid shell fragments.  The Gd(III)-bound 
microbubbles successfully induced BBB opening at a pressure threshold of 0.45 MPa.  This 
threshold corresponded to that used to open the BBB using 4-5 micron and 6-8 micron sized 
microbubbles without Gd(III)-DOTA.  The increase in T1-weighted MRI contrast after injection 
of Omniscan was used to confirm BBB opening at the sonicated region.  There was no 
observable increase in T1-weighted contrast in the sonicated region after FUS application in the 
presence of the Gd(III)-bound microbubbles. 
 
6.2.  Impact on the Field 
The differential centrifugation technique developed in this thesis has been useful in 
producing the different size classes of microbubbles needed to test the effect of microbubble 
monodispersity in CEUS studies.  For instance, Sirsi et al. (Sirsi, Feshitan et al.) demonstrated 
that 4-5 and 6-8 micron diameter offer increased acoustic signal and circulation persistence in 
vivo in comparison to polydisperse and 1-2 micron sized microbubbles, which allowed for much 
longer imaging sessions during high-frequency ultrasound imaging. Streeter et al. (Streeter, 




differential centrifugation methodology, provided improved CEUS diagnostics of rat tumors in 
comparison to polydisperse sizes.  
These size-selected microbubbles have also been extensively studied and adapted in 
applications involving opening the BBB with FUS.  Choi et al. (Choi, Feshitan et al.) was the 
first to demonstrate the dependence of microbubble size on BBB opening with FUS.  The 4-5 
micron sized microbubbles were demonstrated to induce BBB opening in mice at a lower 
acoustic threshold than polydisperse and smaller-sized microbubbles.  Marquet et al. (Marquet, 
Tung et al. 2011) later demonstrated the first successful transcranial BBB opening in non-human 
primates using FUS and 4-5 micron size-selected microbubbles. Subsequently, Vlachos et al. 
(Vlachos, Tung et al. 2011) studied the permeability of BBB opening in the hippocampus of 
mice after the application of FUS at different acoustic pressures and microbubble sizes. Using 
dynamic contrast-enhanced MRI, the volume of BBB opening was determined to be proportional 
to both acoustic pressure and microbubble diameter. Tung et al. (Tung, Vlachos et al. 2011) later 
explored the mechanism of BBB opening by comparing the efficacy of 1-2, 4-5 and 6-8 micron 
size-selected classes. It was demonstrated that BBB opens with nonlinear bubble oscillation 
when the bubble size is closer to the capillary diameter and with inertial cavitation when it is 
much smaller than the capillary diameter.  The volume of opening was demonstrated to increase 
with both pressure and microbubble diameter.  Finally, Samiotaki et al. (Samiotaki, Vlachos et 
al. 2012) demonstrated the dependence of the reversibility of BBB opening in mice on the peak-
rarefactional pressure and microbubble size using contrast-enhanced MRI.  
The MR behavior of the size-selected lipid-stabilized Gd(III)-bound microbubbles may 
ultimately prove to be beneficial in the biomedical field. One proposed application for these 




microbubble fragmentation state with MRI as opposed to the conventionally method of MR 
thermometry.  For instance, owing to the observed differences in longitudinal relaxivity between 
the intact and fragmented constructs, T1-weighted MRI along with the lipid-headgroup labeled 
(Gd(III)-PE) microbubbles can potentially be used to monitor microbubble fragmentation state 
during FUS therapy. Alternatively, due to the observed differences in transverse relativity of 
intact and fragmented constructs, the PEG labeled Gd(III)-microbubbles and microbubbles 
without Gd(III) may provide the option to use the T2*-weighted MRI to monitor microbubble 
fragmentation state. 
.  
6.3. Future Directions 
 
The next step in adapting the size-selection methodology is the development of 
continuous size selection process as opposed to the batch system used in this thesis.  One 
possibility is the design of a continuous-flow centrifugal separator that consists of a process input 
(containing the polydisperse suspension), a process output (containing the size-separated 
microbubbles) and a recycle stream for added efficiency.  This approach may reduce 
microbubble separation time and minimize the error associated with operator handling that stems 
from the batch separation method. 
Additional studies on the parameters affecting the relaxivity of the Gd(III)-bound lipid 
microbubbles should also be explored in the future. This includes determining the dependence of 
varying microbubble shell parameters and gas composition on the relaxivity of Gd(III)-bound 
construct.  For instance, microbubbles with a paramagnetic gas composition such as Oxygen may 




Nitrogen. Moreover, the effects of changing external parameters such as the magnetic field 
strength and local temperature should also be considered in subsequent analysis.   
The next step in understanding the behavior of Gd(III)-bound lipid microbubbles in vivo 
is to adapt techniques that improve the chances of tracking the Gd(III)-bound shell.  In the BBB 
opening study performed in chapter 5, the main drawback in detecting the shell fragments at the 
sonicated hippocampus was the delay between scanning with MRI and FUS sonications. This 
limitation stemmed from the inherent differences in accessibility of both equipments during 
experimentation. In order to improve the chances of imaging the shell fragments, it is preferable 
to utilize an integrated MRI and FUS device similar to the Exablate 2000 (InSightec, Ltd), which 
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